The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Prefilled Syringes Market (5th Edition), 2020-2030

  • Lowest Price Guaranteed From USD 4,899

  • Published
    January 2020

  • Pages
    811

  • View Count
    7754

Example Insights

Prefilled Syringes Market (5th Edition), 2019-2030-Context Prefilled Syringes Market (5th Edition), 2019-2030-List of syringes manufacturers Prefilled Syringes Market (5th Edition), 2019-2030-Combination Products
Prefilled Syringes Market (5th Edition), 2019-2030-Product Competitiveness analysis Prefilled Syringes Market (5th Edition), 2019-2030-Fill Finish Service providers Prefilled Syringes Market (5th Edition), 2019-2030-Big pharma initiatives
Prefilled Syringes Market (5th Edition), 2019-2030-Pipeline Prefilled Syringes Market (5th Edition), 2019-2030-Market Forecast 	Prefilled Syringes Market (5th Edition), 2019-2030-Futuer Forecast

 

Overview

We are seeing an increased demand in the emerging markets, particularly within the BRICS nations, namely Brazil, Russia, India, China and South Africa. North Africa and the Middle East also present a similar scenario, characterized by a growth rate of 10-18% for prefilled syringes

-- Marketing Director, a large-sized company

According to experts in the healthcare industry, one in three adults are estimated to be suffering from some type of chronic clinical condition, such as multiple sclerosis, diabetes, rheumatoid arthritis and cardiovascular diseases. Chronic clinical conditions are considered to be among the leading causes of death and disability across the world.  Typically, in such cases, individuals are required to medicate on a daily basis. In addition to the cost of medication, such individuals are also burdened with a deteriorating quality of life, and often struggle with medication adherence.  According to the US Centers for Disease Control (CDC), the overall annual expense incurred by those living with chronic diseases is steadily growing and is currently estimated to be more than USD 3 trillion.  The development and commercialization of self-administrable dosage forms of drugs indicated to treat chronic clinical conditions has made a significant positive impact not only on the healthcare expenses borne by patients but also on compliance to prescribed therapeutic regimens. As the number of patients suffering from such disorders increase, the demand for more convenient and patient friendly drug delivery solutions is also on the rise. 

Most self-injection devices / systems, such as autoinjectors and pen-injectors,  rely on prefilled syringes, which serve as primary drug containers in the aforementioned products. Moreover, despite having been in the market for more than three decades now, the overall interest in prefilled syringes continues to grow. In fact, the recent increase in use of biologics, which are usually administered via parenteral routes, has had a significant impact on the demand for prefilled syringes.  Over the years, significant improvements have been made to conventional prefilled syringes in order to further expand the scope of their applications. In this context, it is worth mentioning that dual / multi chambered syringes designed for the administration of lyophilized drugs are already available in the market. In such products, the syringe barrel is divided into two chambers, one of which contains the appropriate diluent for the prefilled (lyophilized) drug formulation. Likewise, there are multiple types of specialty syringes, including contrast agent containing syringes and flush syringes. Further, since the introduction and enforcement of the Needlestick Safety and Prevention Act in 2000, several medical device manufactures have developed add-on or integrated safety devices for prefilled syringes. In fact, by 2020, the incorporation of safety features in prefilled syringes is anticipated to be made mandatory across the world. The ongoing COVID-19 pandemic has increased the number of development programs for vaccines, significantly raising the demand for manufacturing prefilled syringes in the foreseen future.

Scope of the Report

The ‘Prefilled Syringes Market (5th edition), 2019-2030’ report features an extensive study of the current market landscape of prefilled syringes and the likely future opportunities associated with such devices, over the next 10-12 years. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current market landscape of companies engaged in manufacturing prefilled syringes, providing information on year of establishment, company size, geographical location of the headquarters and manufacturing facilities, type of material used (glass and plastic), number of barrel chambers (single chamber and dual chamber), type of needle system (fixed needle system, luer lock and luer cone) and syringe volume. 
  • An overview of the current market landscape of companies that are developing drugs in combination with prefilled syringes, featuring information on year of establishment, company size, geographical location of the developers, target therapeutic area, phases of development, type of drug molecule, route of administration, approval year (for marketed products), dosage details (for marketed products) and other approved dosage forms (for marketed products). 
  • A detailed competitiveness analysis of the various prefilled syringes that we came across, taking into consideration the supplier power (based on the employee size of developer / manufacturer and their respective annual revenues) and key product specifications, such as number of chambers in the barrel, number of needle systems, volume of the barrel, technological advancement / user-friendliness and other distinguishing features.
  • A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with prefilled syringes in the near future, shortlisted based on an in-depth analysis that takes into consideration various relevant parameters, such as route of administration, type of drug molecule, target indications, other available dosage forms (for approved drugs) and historical annual sales information (for approved drugs).
  • An analysis presenting potential strategic partners (primarily drug developers) for prefilled syringe manufacturers (with regard to likely collaboration opportunities for combination product development) based on different parameters, such as pipeline strength, target therapeutic indication(s) and developer strength.
  • An analysis of the various prefilled syringe combination product-related initiatives of big pharma players, based on parameters, such as current adoption (based on number of approved and under development prefilled syringe combination products) and likely future adoption (based on potential injectable product candidates in the pipeline that are likely to be delivered via prefilled syringes), target therapeutic area(s) and type of drug molecule.
  • A review of the landscape of contract fill / finish services providers that offer services for prefilled syringes, featuring a list of active (large-sized) service providers and analysis based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), type of drug molecule (biologics and small molecules), and geographical location of the service provider. 
  • A detailed discussion on various safety features (add-on and integrated devices) installed in recent versions of prefilled syringes and the companies involved in developing and manufacturing such solutions.
  • An informative summary of various guidelines established and issued by major regulatory bodies for the approval of prefilled syringes, across different countries / geographical regions.  
  • Brief discussions of currently available specialty syringes, which include prefilled flush syringes, prefilled diluent syringe systems and prefilled contrast agent delivery systems. 
  • A case study on companies that are engaged in the manufacturing of autoinjectors, featuring brief profiles of key players in this domain; each profile includes an overview of the firm, and information on its respective product portfolio.
  • Elaborate profiles of prominent prefilled syringe manufacturers engaged in this domain, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.
  • Elaborate profiles of prominent prefilled syringe component manufacturers, featuring a brief overview of the company, its financial information (if available), information on product portfolio, recent developments and an informed future outlook.

One of the key objectives of the report was to evaluate the current market size and the future opportunity within the prefilled syringes market. Based on various relevant parameters, such as the number of commercialized combination products, annual adoption rate, and expected pricing, we have provided an informed estimate of the likely evolution of the market over the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] therapeutic area (autoimmune disorders, infectious diseases, neurological disorders, blood disorders, oncological disorders, psychiatric disorders, respiratory disorders, cardiovascular disorders, metabolic disorders, ophthalmic diseases, orthopedic disorders and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber), [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)). 

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:

  • Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies)
  • Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals)
  • Gregor Kawaletz (Chief Commercial Officer, IDT Biologika)
  • Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical)
  • Marco Pederiva (Marketing & Sales Director, Lonstroff)
  • Jesse Fourt (Design Director, IDEO)
  • Anonymous (Chief Executive Officer, Small-sized Medical Device Company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Recent Developments

  • UCB teams up with Ferring Pharma to commercialize prefilled syringe Cimzia (source)
  • Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp) (source)

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the prefilled syringes market in the mid to long term.

Chapter 3 provides an introduction to the concept of prefilled syringes, including details on their origin, various affiliated components (such as barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap), fabrication material (glass and plastic), manufacturing-related information, and other critical attributes and features. In addition, the chapter includes a discussion highlighting the future of prefilled syringes. 

Chapter 4 provides an overview of around 80 prefilled syringes that are available in the market and provides details on the companies that manufacture such products. It features analyses of the prefilled syringes, based on various parameters, such as type of material (glass and plastic), number of barrel chambers (dual chamber and single chamber), type of needle system (fixed needle system and luer system) and syringe volume. In addition, the chapter provides information on manufacturers, along with information on year of establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes a discussion on the technological advances of prefilled syringes that have taken place in the recent past.

Chapter 5 presents a product competitiveness analysis of glass and plastic prefilled syringes (separately) based on the supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 6 includes detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook. In addition, the chapter also features short profiles of some of the small and mid-sized manufacturers, highlighting brief overview of the company, product portfolio and recent developments (if available).

Chapter 7 highlights the growing concerns associated with needlestick injuries and the various steps (including regional and global legislations) that have been taken to prevent sharps related mishaps. One of the important risk mitigation strategies covered in this chapter is the installation of safety features in upcoming versions of prefilled syringes. In addition, the chapter provides information on syringe-related safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.

Chapter 8 presents overview of the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the prefilled syringes regulatory requirements and the role of regulatory bodies in the approval of syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 9 provides details on the various pipeline and approved products that are being tested or available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. It features a detailed analysis of these drugs, based on the various parameters, such as the target therapeutic area(s), phase of development, type of drug molecule, route of administration, approval year (in case of marketed products), dosage (in case of marketed products) and other approved dosage forms (in case of marketed products). In addition, the chapter provides information on drug developers, year of their establishment, location of headquarters and manufacturing facilities, and strength of employee base. The chapter also includes case studies of top two marketed drugs available in prefilled syringes, namely Humira® and Enbrel®. 

Chapter 10 features a discussion on the most commonly targeted therapeutic indications, including information on the approved / marketed injectable drug products available for the treatment of such clinical conditions (across different target therapeutic areas) and their respective biosimilars.

Chapter 11 presents a list of marketed and pipeline molecules that are likely to be considered for delivery via prefilled syringes in the future. It is worth highlighting that this list has been compiled based on various parameters, such as route of administration, target therapeutic indication(s), other available dosage forms (in case of marketed drugs), type of drug molecule and drug sales of the approved product candidates. For the purpose of this analysis, we collated a list of over 100 top-selling marketed drugs, which were initially screened on the basis of route of administration (subcutaneous / intramuscular). Additionally, we reviewed over 1,400 clinical trials and compiled a list of pipeline molecules that are being investigated for delivery via the aforementioned routes. The likelihood of delivery via a prefilled syringe in the future was estimated using the weighted average method. Additionally, the chapter features an insightful analysis, highlighting potential strategic partners (primarily drug developers) for prefilled syringes manufacturers, based on multiple parameters, such as pipeline strength, targeted therapeutic indications, and developer strength. The analysis aims to provide the necessary inputs to the latter type of stakeholders, enabling them to make the right decisions to develop combination products.

Chapter 12 highlights top 20 big pharma players engaged or likely to be engaged in the domain of prefilled syringes. It features a benchmarking of the companies based on parameters, such as current adoption (based on number of approved and development-stage prefilled syringe combination products) and likely future adoption (based on potential likely early and late stage pipelines), target therapeutic area(s), and type of drug molecules.

Chapter 13 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and prefilled contrast agent delivery systems. For each type of specialty syringe, we have provided a brief overview and details on the different products that are available in the market and their advantages.

Chapter 14 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advancements in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual chambered syringe systems. The chapter also highlights novel lubrication and sterilization technologies.

Chapter 15 presents an insightful market forecast analysis, highlighting the future potential of the prefilled syringes market till the year 2030. We have segregated the opportunity of the market on the basis of [A] therapeutic area (autoimmune disorders, infectious diseases, neurological disorders, blood disorders, oncological disorders, psychiatric disorders, respiratory disorders, cardiovascular disorders, metabolic disorders, ophthalmic diseases, orthopedic disorders and others), [B] type of syringe, [C] type of material (glass and plastic), [D] number of chambers (single chamber and dual chamber),  [E] type of drug molecule (antibodies, proteins, vaccines, small molecules, peptides, and others), and [F] key geographies (North America, Europe (the UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East)). The analysis presents 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.

Chapter 16 features a detailed discussion on the various factors that are anticipated to drive growth within the prefilled syringes market, such as the rise in preference for self-administration of medication, increase in incidence of chronic diseases, evolving patient landscape, introduction and growing adoption of biologics / biosimilars, initiatives focused on the prevention of needlestick injuries and the various potential applications of prefilled syringes. 

Chapter 17 provides a detailed SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future. 

Chapter 18 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler, Lonstroff, Ompi, West Pharmaceutical and Jiangsu Hualan New Pharmaceutical Material.

Chapter 19 provides an overview of the landscape of pharmaceutical companies that offer fill / finish contract services for prefilled syringes. It includes information related to around 45 contract service providers that are currently active in this domain. It features in-depth analyses based on a number of relevant parameters, such as scale of operation (preclinical, clinical and commercial), type of drug molecules filled (small molecule and biologics), year of establishment, company size and geographical location of the service providers.

Chapter 20 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Elcam Medical, Nuance Designs, Owen Mumford, SHL Group, Union Medico and Ypsomed.

Chapter 21 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 22 is a collection of transcripts of interviews conducted with representatives from renowned organizations that are engaged in the prefilled syringes manufacturing domain. In this chapter, we have presented the details of our conversations with Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Gregor Kawaletz (Chief Commercial Officer, IDT Biologika), Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical), Marco Pederiva (Marketing & Sales Director, Lonstroff), Jesse Fourt (Design Director, IDEO) and Anonymous (Chief Executive Officer, Small-sized Medical Device Company). 

Chapters 23 is an appendix that provides tabulated data and numbers for all the figures included in the report.

Chapter 24 is an appendix that contains the list of companies and organizations mentioned in the report.

Table Of Contents

1 PREFACE
1.1. Chapter Overview
1.2. Scope of the Report
1.3. Research Methodology
1.4. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION TO PREFILLED SYRINGES
3.1. Chapter Overview
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes Over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits to Manufacturers
3.3.3. Shift from Existing Dosage Forms to Prefilled Syringes

3.4. Prefilled Syringe Components
3.5. Classification of Prefilled Syringes
3.5.1. Classification by Barrel Fabrication Material
3.5.1.1. Glass
3.5.1.1.1. Limitations of Glass Barrel Prefilled Syringes
3.5.1.1.2. Addressing the Limitations of Glass Barrel Prefilled Syringes

3.5.1.2. Plastic
3.5.1.2.1. Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.2. Addressing the Limitations of Plastic Barrel Prefilled Syringes
3.5.1.2.3. Factors Likely to Drive the Use of Plastic Barrel Prefilled Syringes

3.5.2. Classification by Number of Chambers in the Barrel 
3.5.3. Classification by Type of Needle System
3.5.4. Classification by Type of Packaging

3.6. Critical Attributes of Prefilled Syringe Design
3.7. Manufacturing Prefilled Syringes
3.7.1. Production of Barrels
3.7.1.1. Glass Barrel Prefilled Syringes
3.7.1.2. Plastic Barrel Prefilled Syringes
3.7.2. Production of Syringes
3.7.3. Barrel Siliconization
3.7.4. Syringe Sterilization
3.7.5. Validation of Sterilization
3.7.6. Syringe Filling
3.7.7. Syringe Testing
3.8. Future of Prefilled Syringes

4 PREFILLED SYRINGES: MARKET OVERVIEW
4.1. Chapter Overview
4.2. Prefilled Syringes: List of Available / Under Development Devices
4.2.1. Analysis by Type of Barrel Fabrication Material
4.2.2. Analysis by Number of Barrel Chambers
4.2.3. Analysis by Type of Needle System
4.2.4. Analysis by Device Capacity

4.3. Prefilled Syringes: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Geographical Location of Headquarters
4.3.4. Analysis by Geographical Location of Manufacturing Facilities

4.4. Technological Developments in Prefilled Syringes

5 PRODUCT COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Product Competitiveness Analysis: Prefilled Syringe Systems
5.4.1. Glass Barrel Prefilled Syringes
5.4.2. Plastic Barrel Prefilled Syringes

6 MANUFACTURERS OF PREFILLED SYRINGES
6.1. Chapter Overview
6.2. Key Prefilled Syringe Manufacturers Based in North America
6.2.1. Becton Dickinson
6.2.1.1. Company Overview
6.2.1.2. Financial Performance
6.2.1.3. Prefilled Technology Solutions
6.2.1.4. Glass Barrel Prefilled Systems
6.2.1.4.1. BD Hypak Prefilled Syringe
6.2.1.4.2. BD Neopak Prefilled Syringe
6.2.1.4.3. BD Hylok Prefilled Syringe
6.2.1.5. Plastic Barrel Prefilled Systems
6.2.1.5.1. BD Sterifill Syringe Systems
6.2.1.6. Other Prefilled Delivery Systems
6.2.1.6.1. BD Uniject
6.2.1.7. Recent Developments
6.2.1.8. Future Outlook

6.2.2. West Pharmaceutical
6.2.2.1. Company Overview
6.2.2.2. Financial Performance
6.2.2.3. Prefilled Technology Solutions
6.2.2.4. Plastic Barrel Prefilled Systems
6.2.2.4.1. Daikyo Crystal Zenith Polymer RTU Prefilled Syringe
6.2.2.5. Drug Reconstitution Systems
6.2.2.6. Recent Developments
6.2.2.7. Future Outlook

6.3. Key Prefilled Syringe Manufacturers Based in Europe
6.3.1. Gerresheimer
6.3.1.1. Company Overview
6.3.1.2. Financial Performance
6.3.1.3. Prefilled Technology Solutions
6.3.1.4. Glass Barrel Prefilled Systems
6.3.1.4.1. Gx Glass Syringes
6.3.1.5. Plastic Barrel Prefilled Systems
6.3.1.5.1. ClearJect Prefilled syringes
6.3.1.5.2. Gx RTF Clearject Needle Syringe
6.3.1.6. Safety Syringes
6.3.1.6.1. Gx InnoSafe Safety Syringes
6.3.1.7. Self-Injection Devices
6.3.1.8. Recent Developments
6.3.1.9. Future Outlook

6.3.2. Ompi
6.3.2.1. Company Overview
6.3.2.2. Financial Performance
6.3.2.3. Glass Barrel Prefilled Systems
6.3.2.3.1. EZ-Fill Syringes
6.3.2.3.1.1. EZ-fill Fina
6.3.2.3.1.2. EZ-fill Nexa
6.3.2.3.1.3. EZ-fill Alba
6.3.2.4. Recent Developments
6.3.2.5. Future Outlook

6.3.3. SCHOTT
6.3.3.1. Company Overview
6.3.3.2. Financial Performance
6.3.3.3. Glass Barrel Prefilled Syringes
6.3.3.3.1. syriQ Glass Syringes
6.3.3.4. Plastic Barrel Prefilled Syringes
6.3.3.4.1. TopPac Polymer Syringes
6.3.3.5. Recent Developments
6.3.3.6. Future Outlook

6.4. Key Prefilled Syringe Manufacturers in Asia
6.4.1. Nipro (Acquired MGlas)
6.4.1.1. Company Overview
6.4.1.2. Financial Performance
6.4.1.3. Glass Barrel Prefilled Systems
6.4.1.4. Recent Developments
6.4.1.5. Future Outlook

6.4.2. WEGO Prefills Pharmaceutical Packaging
6.4.2.1. Company Overview
6.4.2.2. Financial Performance
6.4.2.3. WeGo Glass Prefilled Syringe
6.4.2.4. Weigao Prefilled Flush Syringes
6.4.2.5. Future Outlook

6.4.3. Taisei Kako
6.4.3.1. Company Overview
6.4.3.2. Glass Barrel Prefilled Systems
6.4.3.2.1. VF-Syringe
6.4.3.2.1. SIN-Syringe
6.4.3.3. Plastic Barrel Prefilled System
6.4.3.3.1. ClearJect Syringes
6.4.3.3.2. FULJECT Passive Type Syringe
6.4.3.3.3. Ajex Needleless Injection System
6.4.3.4. Future Outlook

6.4.4. Terumo
6.4.4.1. Company Overview
6.4.4.2. Financial Performance
6.4.4.3. Plastic Barrel Prefilled Syringe
6.4.4.4. Safety Devices: Add-On Devices
6.4.4.5. Recent Developments
6.4.4.6. Future Outlook

6.5. Other Manufacturers
6.5.1. Aguettant
6.5.1.1. Company Overview
6.5.1.2. Prefilled Syringe Portfolio
6.5.1.2.1. Aguettant Prefilled Syringe
6.5.1.3. Recent Developments

6.5.2. Arte
6.5.2.1. Company Overview
6.5.2.2. Prefilled Syringe Portfolio
6.5.2.2.1. Dual Chamber Prefillable Syringe
6.5.2.2.2. Single Chamber Prefillable Syringe

6.5.3. J.O. Pharma (Subsidiary of Otsuka Holdings)
6.5.3.1. Company Overview
6.5.3.2. Prefilled Syringe Portfolio

6.5.4. Pfizer Injectables
6.5.4.1. Company Overview
6.5.4.2. Prefilled Syringe Portfolio
6.5.4.2.1. ABBOJECT Syringe
6.5.4.2.2. Emergency Syringes
6.5.4.2.3. iSecure Syringe System

6.5.5. Shandong Pharmaceutical Glass
6.5.5.1. Company Overview
6.5.5.2. Prefilled Syringe Portfolio

6.5.6. Shandong Zibo Minkang Pharmaceutical packing
6.5.6.1. Company Overview
6.5.6.2. Prefilled Syringe Portfolio

6.5.7. Vetter Pharma
6.5.7.1. Company Overview
6.5.7.2. Prefilled Syringe Portfolio
6.5.7.2.1. Lyo-Ject Glass Prefilled Syringe
6.5.7.2.2. Vetter-Ject Safety Device
6.5.7.2.3. V-OVS Safety Device
6.5.7.3. Recent Developments

7. NEEDLESTICK INJURIES
7.1. Chapter Overview
7.2. Incidence and Associated Financial Burden
7.3. Government Legislations for Prevention of Needlestick Injuries

7.4. Safety Mechanisms Used in Modern Prefilled Syringes
7.4.1. Safety Systems: Add-On Safety Device Manufacturers
7.4.1.1. Becton Dickinson
7.4.1.2. Catalent
7.4.1.3. Terumo
7.4.1.4. Tip-Top
7.4.1.5. West Pharmaceutical

7.4.2. Safety Systems: Integrated Safety Device Manufacturers
7.4.2.1. Gerresheimer
7.4.2.2. Injecto
7.4.2.3. MedicalChain International
7.4.2.4. OMPI
7.4.2.5. Owen Mumford
7.4.2.6. SHL Group
7.4.2.7. Taisei Kako

8 REGULATORY LANDSCAPE FOR PREFILLED SYRINGES
8.1. Chapter Overview
8.2. Regulatory Approval of Combination Products in the US
8.2.1. Overview
8.2.2. Historical Background
8.2.3. Regulatory Bodies and their Role in Product Approval
8.2.4. Regulatory Approval for Prefilled Syringes

8.3. Regulatory Approval of Combination Products in Europe
8.3.1. Overview
8.3.2. Regulatory Bodies and their Role in Product Approval
8.3.3. Regulatory Approval for Prefilled Syringes

8.4. Regulatory Approval of Combination Products in Canada
8.4.1. Overview
8.4.2. Regulatory Bodies and their Role in Product Approval
8.4.3. Regulatory Approval for Prefilled Syringes 

8.5. Regulatory Approval of Combination Products in Brazil
8.5.1. Overview
8.5.2. Regulatory Bodies and their Role in Product Approval
8.5.3. Regulatory Approval for Prefilled Syringes 

8.6. Regulatory Approval of Combination Products in Mexico
8.6.1. Overview
8.6.2. Regulatory Bodies and their Role in Product Approval
8.6.3. Regulatory Approval for Prefilled Syringes 

8.7. Regulatory Approval of Combination Products in Argentina
8.7.1. Overview
8.7.2. Regulatory Bodies and their Role in Product Approval
8.7.3. Regulatory Approval for Prefilled Syringes 

8.8. Regulatory Approval of Combination Products in Australia
8.8.1. Overview
8.8.2. Regulatory Bodies and their Role in Product Approval
8.8.3. Regulatory Approval for Prefilled Syringes 

8.9. Regulatory Approval of Combination Products in Japan
8.9.1. Overview
8.9.2. Regulatory Bodies and their Role in Product Approval
8.9.3. Regulatory Approval for Prefilled syringes 

8.10. Regulatory Approval of Combination Products in China
8.10.1. Overview
8.10.2. Regulatory Bodies and their Role in Product Approval
8.10.3. Regulatory Approval for Prefilled syringes 

8.11. Regulatory Approval of Combination Products in India
8.11.1. Overview
8.11.2. Regulatory Bodies and their Role in Product Approval
8.11.3. Regulatory Approval for Prefilled Syringes 

8.12. Regulatory Approval of Combination Products in South Korea
8.12.1. Overview
8.12.2. Regulatory Bodies and their Role in Product Approval
8.12.3. Regulatory Approval for Prefilled Syringes 

8.13. Regulatory Approval of Combination Products in Saudi Arabia
8.13.1. Overview
8.13.2. Regulatory Bodies and their Role in Product Approval
8.13.3. Regulatory Approval for Prefilled Syringes

8.14. Regulatory Approval of Combination Products in United Arab Emirates
8.14.1. Overview
8.14.2. Regulatory Bodies and their Role in Product Approval
8.14.3. Regulatory Approval for Prefilled Syringes 

9. PREFILLED SYRINGE COMBINATION PRODUCTS: MARKET OVERVIEW
9.1. Chapter Overview
9.2. Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019
9.2.1. Analysis by Type of Drug Molecule
9.2.2. Analysis by Approval Year 
9.2.3. Analysis by Route of Administration 
9.2.4. Analysis by Target Therapeutic Area
9.2.5. Prefilled Syringe Combination Products: Additional Information
9.2.5.1. Analysis by Dose Strength
9.2.5.2. Analysis by Other Approved Dosage Forms

9.3. Prefilled Syringe Combination Products: List of Clinical Stage Drugs, 2013-2019
9.3.1. Analysis by Type of Drug Molecule 
9.3.2. Analysis by Phase of Development 
9.3.3. Analysis by Route of Administration
9.3.4. Analysis by Target Therapeutic Area

9.4. Prefilled Syringe Combination Products: List of Developers
9.4.1. Analysis by Year of Establishment
9.4.2. Analysis by Company Size
9.4.3. Analysis by Geographical Location of Headquarters

9.5. Leading Drugs in Prefilled Syringes
9.6. Other Drugs Available in Prefilled Syringes
9.7. Popular Drugs in Prefilled Syringes: Case Studies
9.7.1. HUMIRA® (Adalimumab), AbbVie / Eisai
9.7.1.1. Target Indications and Available Dosage Forms
9.7.1.2. Shift from Vials to Syringes
9.7.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
9.7.2.1. Target Indications and Available Dosage Forms
9.7.2.2. Shift from Vials to Syringes

10 KEY THERAPEUTIC AREAS
10.1. Chapter Overview
10.1.1. Autoimmune Disorders
10.1.1.1. Approved Injectables
10.1.1.2. Biosimilars

10.1.2. Infectious Diseases
10.1.2.1. Antiviral Drugs
10.1.2.1.1. Approved Injectables
10.1.2.1.2. Biosimilars
10.1.2.2. Vaccines
10.1.2.2.1. Approved Injectables

10.1.3. Neurological Disorders
10.1.3.1. Approved Injectables
10.1.3.2. Biosimilars

10.1.4. Metabolic Disorders
10.1.4.1. Approved Injectables
10.1.4.2. Biosimilars

11 PREFILLED SYRINGES LIKELY DRUG CANDIDATES AND PARTNER   ANALYSIS
11.1. Chapter Overview
11.2. Likely Drug Candidates
11.2.1. Methdology and Key Parameters

11.3. Marketed Drug Candidates
11.3.1. Most Likely Candidates for Delivery via Prefilled Syringes
11.3.2. Likely Candidates for Delivery via Prefilled Syringes
11.3.3. Less Likely Candidates for Delivery via Prefilled Syringes
11.3.4. Least Likely Candidates for Delivery via Prefilled Syringes

11.4. Clinical Drug Candidates
11.4.1. Most Likely Candidates for Delivery via Prefilled Syringes
11.4.2. Likely Candidates for Delivery via Prefilled Syringes
11.4.3. Less Likely Candidates for Delivery via Prefilled Syringes
11.4.4. Least Likely Candidates for Delivery via Prefilled Syringes

11.5. Potential Strategic Partners
11.5.1. Methodology and Key Parameters
11.5.2. Opportunities in North America
11.5.2.1. Most Likely Partners for Prefilled Syringes Combination Product Development
11.5.2.2. Likely Partners for Prefilled Syringes Combination Product Development
11.5.2.3. Less Likely Partners for Prefilled Syringes Combination Product Development
11.5.2.4. Least Likely Partners for Prefilled Syringes Combination Product Development

11.5.3. Opportunities in Europe
11.5.3.1. Most Likely Partners for Prefilled Syringes Combination Product Development
11.5.3.2. Likely Partners for Prefilled Syringes Combination Product Development
11.5.3.3. Less Likely Partners for Prefilled Syringes Combination Product Development
11.5.3.4. Unlikely Partners for Prefilled Syringes Combination Product Development

11.5.4. Opportunities in Asia-Pacific and Rest of the World
11.5.4.1. Most Likely Partners for Prefilled Syringes Combination Product Development
11.5.4.2. Likely Partners for Prefilled Syringes Combination Product Development
11.5.4.3. Less Likely Partners for Prefilled Syringes Combination Product Development
11.5.4.4. Least Likely Partners for Prefilled Syringes Combination Product Development

12 BIG PHARMA INITIATIVES: PREFILLED SYRINGE COMBINATION PRODUCTS AND LIKELY CANDIDATES
12.1. Chapter Overview
12.2. Methdology
12.3. Top Pharmaceutical Companies
12.3.1. Analysis by Therapeutic Area
12.3.1.1. Autoimmune Disorders
12.3.1.2. Infectious Diseases
12.3.1.3. Oncological Disorders
12.3.1.4. Metabolic Disorders
12.3.1.5. Neurological Disorders
12.3.1.6. Inflammatory Disorders
12.3.1.7. Orthopedic Disorders
12.3.1.8. Others

12.3.2. Analysis by Type of Molecule
12.3.2.1. Antibodies
12.3.2.2. Vaccines
12.3.2.3. Proteins
12.3.2.4. Others

13 SPECIALTY PREFILLED SYRINGES
13.1. Chapter Overview
13.2. Prefilled Flush Syringes
13.2.1. Overview
13.2.2. Prefilled Flush Syringes Available in the Market
13.2.3. Advantages of Prefilled Flush Syringes

13.3. Prefilled Diluent Syringes
13.3.1. Overview
13.3.2. Lyophilized Drugs Available in Prefilled Diluent Syringes
13.3.3. Advantages of Prefilled Diluent Syringes

13.4. Contrast Agent Prefilled Syringes
13.4.1. Overview
13.4.2. Contrast Agents Available in Prefilled Syringes
13.4.3. Advantages of Contrast Agent Prefilled Syringes 

14 RECENT DEVELOPMENTS AND APPLICATIONS OF PREFILLED  SYRINGES
14.1. Chapter Overview
14.2. Prefilled Syringes For Lyophilized Drugs
14.2.1. Prefilled Diluent Syringes
14.2.2. Prefilled Dual / Multi-Chamber Prefilled Syringes
14.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringes
14.2.2.2. Prefilled Dual-Chambered Prefilled Pen Injectors for Lyophilized Drugs

14.3. Prefilled Syringes for Ophthalmic Delivery
14.4. Prefilled Syringes for Dermal Fillers
14.5. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
14.6. Prefilled Syringes with Low Particle Formation Risk
14.7. Lubrication Technology for Prefilled Syringes

14.8. Advances in Terminal Sterilization of Prefilled Syringes
14.8.1. Noxilizer’s  Nitrogen Dioxide Sterilization Technology
14.9. Prefilled Syringes Usage Aids for Patients and Healthcare Providers

15 MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Methodology
15.3. Global Prefilled Syringes Market, 2020-2030
15.3.1. Prefilled Syringes Market: Distribution by Therapeutic Area
15.3.1.1. Prefilled Syringes Market: Autoimmune Disorders
15.3.1.2. Prefilled Syringes Market: Infectious Diseases
15.3.1.3. Prefilled Syringes Market: Neurological Disorders
15.3.1.4. Prefilled Syringes Market: Blood Disorders
15.3.1.5. Prefilled Syringes Market: Oncological Disorders
15.3.1.6. Prefilled Syringes Market: Psychiatric Diseases
15.3.1.7. Prefilled Syringes Market: Respiratory Disorders
15.3.1.8. Prefilled Syringes Market: Cardiovascular Disorders
15.3.1.9. Prefilled Syringes Market: Metabolic Disorders
15.3.1.10. Prefilled Syringes Market: Ophthalmic Disorder
15.3.1.11. Prefilled Syringes Market: Orthopedic Disorders
15.3.1.12. Prefilled Syringes Market: Other Diseases
 
15.3.2. Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material
15.3.2.1. Prefilled Syringes Market: Glass Barrel Prefilled Syringes
15.3.2.2. Prefilled Syringes Market: Plastic Barrel Prefilled Syringes
 
15.3.3. Prefilled Syringes Market: Distribution by Type of Chamber System
15.3.3.1. Prefilled Syringes Market: Single Chamber Prefilled Syringes
15.3.3.2. Prefilled Syringes Market: Dual Chamber Prefilled Syringes
 
15.3.4. Prefilled Syringes Market: Distribution by Type of Drug Molecule
15.3.4.1. Prefilled Syringes Market: Antibodies
15.3.4.2. Prefilled Syringes Market: Proteins
15.3.4.3. Prefilled Syringes Market: Peptides
15.3.4.4. Prefilled Syringes Market: Small Molecules
15.3.4.5. Prefilled Syringes Market: Vaccines
 
15.3.5. Prefilled Syringes Market: Distribution by Geography
15.3.5.1. Prefilled Syringes Market: North America
15.3.5.2. Prefilled Syringes Market: Europe
15.3.5.3. Prefilled Syringes Market: Asia Pacific
15.3.5.4. Prefilled Syringes Market: Latin America
15.3.5.5. Prefilled Syringes Market: Middle East and Africa
 
15.3.6. Prefilled Syringes Market: Distribution by Specialty Syringes
15.3.7. Prefilled Syringes Market for Autoimmune Disorders
15.3.7.1. Distribution by Syringe Barrel Material
15.3.7.1.1. Glass Barrel Prefilled Syringes
15.3.7.1.2. Plastic Barrel Prefilled Syringes

15.3.7.2. Distribution by Type of Chamber System
15.3.7.2.1. Single Chamber Prefilled Syringes
15.3.7.2.2. Dual Chamber Prefilled Syringes

15.3.7.3. Distribution by Type of Drug Molecule
15.3.7.3.1. Antibodies
15.3.7.3.2. Proteins
15.3.7.3.3. Small Molecules

15.3.7.4. Distribution by Geography
15.3.7.4.1. North America
15.3.7.4.2. Europe
15.3.7.4.3. Asia Pacific
15.3.7.4.4. Latin America
15.3.7.4.5. Middle East and Africa
 
15.3.8. Prefilled Syringes Market For Infectious Disorders
15.3.8.1. Distribution by Type of Syringe Barrel Material
15.3.8.1.1. Glass Barrel Prefilled Syringes
15.3.8.1.2. Plastic Barrel Prefilled Syringes

15.3.8.2. Distribution by Type of Chamber System
15.3.8.2.1. Single Chamber Prefilled Syringes
15.3.8.2.2. Dual Chamber Prefilled Syringes

15.3.8.3. Distribution by Type of Drug Molecule
15.3.8.3.1. Vaccines

15.3.8.4. Distribution by Geography
15.3.8.4.1. North America
15.3.8.4.2. Europe
15.3.8.4.3. Asia Pacific
15.3.8.4.4. Latin America
15.3.8.4.5. Middle East and Africa
 
15.3.9. Prefilled Syringes Market For Neurological Disorders
15.3.9.1. Distribution by Type of Syringe Barrel Material
15.3.9.1.1. Glass Barrel Prefilled Syringes
15.3.9.1.2. Plastic Barrel Prefilled Syringes

15.3.9.2. Distribution by Type of Chamber System
15.3.9.2.1. Single Chamber Prefilled Syringes
15.3.9.2.2. Dual Chamber Prefilled Syringes

15.3.9.3. Distribution by Type of Drug Molecule
15.3.9.3.1. Antibodies
15.3.9.3.2. Proteins
15.3.9.3.3. Peptides

15.3.9.4. Distribution by Geography
15.3.9.4.1. North America
15.3.9.4.2. Europe
15.3.9.4.3. Asia Pacific
15.3.9.4.4. Latin America
15.3.9.4.5. Middle East and Africa
 
15.3.10. Prefilled Syringes Market For Blood Disorders
15.3.10.1. Distribution by Type of Syringe Barrel Material
15.3.10.1.1. Glass Barrel Prefilled Syringes
15.3.10.1.2. Plastic Barrel Prefilled Syringes

15.3.10.2. Distribution by Type of Chamber System
15.3.10.2.1. Single Chamber Prefilled Syringes
15.3.10.2.2. Dual Chamber Prefilled Syringes

15.3.10.3. Distribution by Type of Drug Molecule
15.3.10.3.1. Proteins
15.3.10.3.2. Small Molecules

15.3.10.4. Distribution by Geography
15.3.10.4.1. North America
15.3.10.4.2. Europe
15.3.10.4.3. Asia Pacific
15.3.10.4.4. Latin America
15.3.10.4.5. Middle East and Africa
 
15.3.11. Prefilled Syringes Market For Oncological Disorders
15.3.11.1. Distribution by Type of Syringe Barrel Material
15.3.11.1.1. Glass Barrel Prefilled Syringes
15.3.11.1.2. Plastic Barrel Prefilled Syringes

15.3.11.2. Distribution by Type of Chamber System
15.3.11.2.1. Single Chamber Prefilled Syringes
15.3.11.2.2. Dual Chamber Prefilled Syringes

15.3.11.3. Distribution by Type of Drug Molecule
15.3.11.3.1. Antibodies
15.3.11.3.2. Proteins
15.3.11.3.3. Peptides
15.3.11.3.4. Small Molecules
15.3.11.3.5. Vaccines

15.3.11.4. Distribution by Geography
15.3.11.4.1. North America
15.3.11.4.2. Europe
15.3.11.4.3. Asia Pacific
15.3.11.4.4. Latin America
15.3.11.4.5. Middle East and Africa
 
15.3.12. Prefilled Syringes Market For Metabolic Disorders
15.3.12.1. Distribution by Type of Syringe Barrel Material
15.3.12.1.1. Glass Barrel Prefilled Syringes
15.3.12.1.2. Plastic Barrel Prefilled Syringes

15.3.12.2. Distribution by Type of Chamber System
15.3.12.2.1. Single Chamber Prefilled Syringes
15.3.12.2.2. Dual Chamber Prefilled Syringes

15.3.12.3. Distribution by Type of Drug Molecule
15.3.12.3.1. Proteins
15.3.12.3.2. Peptides

15.3.12.4. Distribution by Geography
15.3.12.4.1. North America
15.3.12.4.2. Europe
15.3.12.4.3. Asia Pacific
15.3.12.4.4. Latin America
15.3.12.4.5. Middle East and Africa

15.3.13. Prefilled Syringes Market For Other Disorders
15.3.13.1. Distribution by Type of Syringe Barrel Material
15.3.13.1.1. Glass Barrel Prefilled Syringes
15.3.13.1.2. Plastic Barrel Prefilled Syringes

15.3.13.2. Distribution by Type of Chamber System
15.3.13.2.1. Single Chamber Prefilled Syringes
15.3.13.2.2. Dual Chamber Prefilled Syringes

15.3.13.3. Distribution by Type of Drug Molecule
15.3.13.3.1. Antibodies
15.3.13.3.2. Proteins
15.3.13.3.3. Peptides
15.3.13.3.4. Small Molecules

15.3.13.4. Distribution by Geography
15.3.13.4.1. North America
15.3.13.4.2. Europe
15.3.13.4.3. Asia Pacific
15.3.13.4.4. Latin America
15.3.13.4.5. Middle East and Africa

16 GROWTH DRIVERS
16.1. Chapter Overview
16.2. Rising Incidence of Chronic Diseases
16.3. Growing Preference for Self-Injection
16.4. Evolving Patient Demographics
16.5. Growth of Biologics and Biosimilars Market
16.6. Changing Pharmaceutical Strategies
16.7. Increasing Focus on Prevention of Needlestick Injuries
16.8. Prefilled Syringes in Autoinjectors and Pen Injectors

17 SWOT ANALYSIS
17.1. Chapter Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
17.6. Concluding Remarks

18 PREFILLED SYRINGE COMPONENT MANUFACTURERS
18.1. Chapter Overview
18.2. List of Component Manufacturers
18.3. Aptar Pharma (a Part of AptarGroup)
18.3.1. Company Overview
18.3.2. Financial Performance
18.3.3. Product Portfolio
18.3.4. Recent Developments and Future Outlook

18.4. West Pharmaceutical
18.4.1. Company Overview
18.4.2. Financial Performance
18.4.3. Product Portfolio
18.4.4. Recent Developments and Future Outlook

18.5. Datwyler Sealing Solutions (a Part of Datwyler Group)
18.5.1. Company Overview
18.5.2. Financial Performance
18.5.3. Product Portfolio
18.5.4. Recent Developments and Future Outlook

18.6. Lonstroff (a Part of Sumitomo Rubber Industries)
18.6.1. Company Overview
18.6.2. Financial Performance
18.6.3. Product Portfolio
18.6.4. Recent Developments and Future Outlook

18.7. Ompi (a Part of Stevanato Group)
18.7.1. Company Overview
18.7.2. Product Portfolio
18.7.3. Recent Developments and Future Outlook

18.8. Jiangsu Hualan Pharmaceutical New Material
18.8.1. Company Overview
18.8.2. Product Portfolio
18.8.3. Recent Developments and Future Outlook

19 FILL / FINISH SERVICE PROVIDERS FOR PREFILLED SYRINGES
19.1. Chapter Overview
19.2. Fill / Finish Processing of Prefilled Syringes
19.2.1. Steps Involved in Fill / Finish Process
19.2.2. Methods of Filling and Stoppering of Prefilled Syringes
19.2.3. Prefilled Syringe Filling Technologies

19.3. Outsourcing of Fill / Finish Operations
19.4. Growth Considerations
19.5. Prefilled Syringes: List of Fill / Finish Service Providers
19.5.1. Analysis by Year of Establishment
19.5.2. Analysis by Geographical Location of Headquarters and Type of Drug Molecule
19.5.3. Analysis by Scale of Operation  

20 CASE STUDY: AUTOINJECTORS
20.1. Chapter Overview
20.2. Autoinjectors: Market Overview

20.3. Key Players
20.3.1. Elcam Medical (E3D Elcam Drug Delivery Devices)
20.3.1.1. Company Overview
20.3.1.2. Product Portfolio

20.3.2. Nuance Designs
20.3.2.1. Company Overview
20.3.2.2. Product Portfolio

20.3.3. Owen Mumford
20.3.3.1. Company Overview
20.3.3.2. Product Portfolio

20.3.4. Scandinavian Health Limited (SHL) Group
20.3.4.1. Company Overview
20.3.4.2. Product Portfolio

20.3.5. Union Medico
20.3.5.1. Company Overview
20.3.5.2. Product Portfolio

20.3.6. Ypsomed
20.3.6.1. Company Overview
20.3.6.2. Product Portfolio

21 CONCLUDING REMARKS
21.1. Chapter Overview
21.2. Key Takeaways

22 INTERVIEW TRANSCRIPTS
22.1. Chapter Overview
22.2. Oval Medical Technologies
22.2.1. Company Snapshot
22.2.2. Interview Transcript: Matthew Young, Founder and Chief Technology Officer

22.3. Intas Pharmaceuticals
22.3.1. Company Snapshot
22.3.2. Interview Transcript: Kirti Maheshwari, Chief Technical Officer

22.4. IDT Biologika
22.4.1. Company Snapshot
22.4.2. Interview Transcript: Gregor Kawaletz, Chief Commercial Officer

22.5. West Pharmaceutical
22.5.1. Company Snapshot
22.5.2. Interview Transcript: Kevin Cancelliere and Tibor Hlobik, Marketing Directors

22.6. Lonstroff
22.6.1. Company Snapshot
22.6.2. Interview Transcript: Marco Pederiva, Marketing and Sales Directors

22.7. IDEO
22.7.1. Company Snapshot
22.7.2. Interview Transcript: Jesse Fourt, Design Director

22.8. Small-sized Medical Device Company
22.8.1. Interview Transcript: Anonymous, Chief Executive Officer

23 APPENDIX 1: TABULATED DATA

24 APPENDIX 2: LIST OF COMPANIES

List Of Figuers

Figure 3.1 Glass Barrel Prefilled Syringes: Advantages and Disadvantages
Figure 3.2 Plastic Barrel Prefilled Syringes: Advantages and Disadvantages
Figure 3.3 Critical Design Parameters of Prefilled Syringes
Figure 3.4 Prefilled Syringe Manufacturing: Common Process
Figure 4.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Figure 4.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 4.3 Prefilled Syringes: Distribution by Type of Needle System
Figure 4.4 Prefilled Syringes: Distribution by Device Capacity
Figure 4.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Figure 4.6 Prefilled Syringe Developers: Distribution by Company Size
Figure 4.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters 
Figure 4.8 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
Figure 4.9 Technological Evolution of Prefilled Syringes
Figure 5.1 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 5.2 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 6.1 BD Medical: Annual Revenues, FY 2010-11 - FY 2017-18 (USD Billion)
Figure 6.2 BD Medical: Revenue Distribution by Sub-Segments, FY 2017-18 (USD Billion)
Figure 6.3 West Pharmaceutical: Annual Revenues, 2011 - H1 2019 (USD Million)
Figure 6.4 West Pharmaceutical: Revenue Distribution by Business Segments, 2018 (USD Million)
Figure 6.5 West Pharmaceutical: Revenue Distribution by Region, 2018 (USD Million)
Figure 6.6 Gerresheimer: Annual Revenues, FY 2010-11 - H1 2018-19 (EUR Million)
Figure 6.7 Gerresheimer: Revenue Distribution by Business Divisions, FY 2017-18 (EUR Million)
Figure 6.8 Gerresheimer: Revenue Distribution by Region, FY 2017-18 (EUR Million)
Figure 6.9 SCHOTT: Annual Revenues, FY 2012-13 - FY 2018-19 (EUR
Million)
Figure 6.10 SCHOTT: Revenue Distribution by Geography, FY 2018-19 (EUR Million)
Figure 6.11 Nipro: Annual Revenues, FY 2011-12 – FY 2018-19 (JPY Billion)
Figure 6.12 Nipro: Revenue Distribution by Business Divisions, FY 2018-19 (JPY Billion)
Figure 6.13 Nipro: Revenue Distribution by Region, FY 2018-19 (JPY Billion)
Figure 6.14 Weigao: Annual Revenues, 2016-H12019 (RMB Billion)
Figure 6.15 Weigao: Revenue Distribution by Principle Products, H1 2019 (RMB Million)
Figure 6.16 Terumo: Annual Revenues, FY 2011-12 - FY 2018-19 (JPY Billion)
Figure 6.17 Terumo: Revenue Distribution by Business Divisions, FY 2017-18 (JPY Billion)
Figure 6.18 Terumo: Revenue Distribution by Region, FY 2017-18 (JPY Billion)
Figure 7.1 Worldwide Evolution in Healthcare Safety Legislation
Figure 8.1 Global Regulations Related to Prefilled Syringes
Figure 8.2 Approval Pathway for Combination Products in the US
Figure 8.3 Approval Pathway for Combination Products in Canada
Figure 8.4 Pharmaceuticals and Medical Devices Agency: Review / Approval Process
Figure 8.5 Approval Pathway for Combination Products in China
Figure 9.1 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Figure 9.2 Approved Prefilled Syringe Combination Products: Distribution by Approval Year 
Figure 9.3 Approved Prefilled Syringe Combination Products: Distribution by Approval Geographies
Figure 9.4 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration 
Figure 9.5 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Figure 9.6 Approved Prefilled Syringes Combination Products: Distribution by Other Dosage Forms
Figure 9.7 Clinical Stage Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule 
Figure 9.8 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development 
Figure 9.9 Clinical Stage Prefilled Syringes Combination Products: Distribution by Route of Administration
Figure 9.10 Approved Prefilled Syringes Combination Products: Distribution by Target Therapeutic Area
Figure 9.11 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Figure 9.12 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Figure 9.13 Prefilled Syringe Combination Product Developers: Distribution by Geographical Location of Headquarters
Figure 9.14 Sales of Leading Drugs Available in Prefilled Syringes, 2018 (USD Billion)
Figure 9.15 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 9.16 HUMIRA®: Approval Timeline for Different Dosage Forms (US and EU)
Figure 9.17 HUMIRA®: Annual Sales, 2003-Q3 2019 (USD Million)
Figure 9.18Enbrel®: Approval Timeline (US and EU)
Figure 9.19 Enbrel®: Approval Timeline for Different Dosage Forms (US and EU)
Figure 9.20 Enbrel®: Annual Sales in the US and Canada, 2002-2018 (USD Million)
Figure 9.21 Enbrel®: Annual Sales outside US and Canada, 2010-2018 (USD Million)
Figure 12.1 Big Pharma Initiatives: Analysis by Therapeutic Area
Figure 12.2 Big Pharma Initiatives: Autoimmune Disorders 
Figure 12.3 Big Pharma Initiatives for Autoimmune Disorders: Analysis by Target Indication
Figure 12.4 Big Pharma Initiatives: Infectious Diseases
Figure 12.5 Big Pharma Initiatives for Infectious Diseases: Analysis by Target Indication
Figure 12.6 Big Pharma Initiatives: Neurological Disorders 
Figure 12.7 Big Pharma Initiatives for Neurological Disorders: Analysis by Target Indication
Figure 12.8 Big Pharma Initiatives: Oncologic Disorders 
Figure 12.9 Big Pharma Initiatives for Oncologic Disorders: Analysis by Target Indication
Figure 12.10 Big Pharma Initiatives: Orthopedic Disorders 
Figure 12.11 Big Pharma Initiatives for Orthopedic Disorders: Analysis by Target Indication
Figure 12.12 Big Pharma Initiatives: Metabolic Disorders 
Figure 12.13 Big Pharma Initiatives for Metabolic Disorders: Analysis by Target Indication
Figure 12.14 Big Pharma Initiatives: Inflammatory Disorders 
Figure 12.15 Big Pharma Initiatives for Inflammatory Disorders: Analysis by Target Indication
Figure 12.16 Big Pharma Initiatives: Other Disorders
Figure 12.17 Big Pharma Initiatives: Analysis by Type of Drug Molecule
Figure 12.18 Big Pharma Initiatives: Analysis by Antibodies
Figure 12.19 Big Pharma Initiatives: Analysis by Proteins 
Figure 12.20 Big Pharma Initiatives: Analysis by Vaccines 
Figure 12.21 Big Pharma Initiatives: Analysis by Other Molecules
Figure 15.1 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Figure 15.2 Global Prefilled Syringes Market, 2020-2030 (Million Units)
Figure 15.3 Global Prefilled Syringes Market, 2020-2030 (USD Million)
Figure 15.4 Prefilled Syringes Market: Distribution by Therapeutic Area, 2020-2030
Figure 15.5 Prefilled Syringes Market: Share of Autoimmune Disorders, 2020-2030 (Million Units)
Figure 15.6 Prefilled Syringes Market: Share of Autoimmune Disorders, 2020-2030 (USD Million)
Figure 15.7 Prefilled Syringes Market: Share of Infectious Diseases, 2020-2030 (Million Units)
Figure 15.8 Prefilled Syringes Market: Share of Infectious Diseases, 2020-2030 (USD Million)
Figure 15.9 Prefilled Syringes Market: Share of Neurological Disorders, 2020-2030 (Million Units)
Figure 15.10 Prefilled Syringes Market: Share of Neurological Disorders, 2020-2030 (USD Million)
Figure 15.11 Prefilled Syringes Market: Share of Blood Disorders, 2020-2030 (Million Units)
Figure 15.12 Prefilled Syringes Market: Share of Blood Disorders, 2020-2030 (USD Million)
Figure 15.13 Prefilled Syringes Market: Share of Oncological Disorders, 2020-2030 (Million Units)
Figure 15.14 Prefilled Syringes Market: Share of Oncological Disorders, 2020-2030 (USD Million)
Figure 15.15 Prefilled Syringes Market: Share of Psychiatric Diseases, 2020-2030 (Million Units)
Figure 15.16 Prefilled Syringes Market: Share of Psychiatric Diseases, 2020-2030 (USD Million)
Figure 15.17 Prefilled Syringes Market: Share of Respiratory Disorders, 2020-2030 (Million Units)
Figure 15.18 Prefilled Syringes Market: Share of Respiratory Disorders, 2020-2030 (USD Million)
Figure 15.19 Prefilled Syringes Market: Share of Cardiovascular Disorders, 2020-2030 (Million Units)
Figure 15.20 Prefilled Syringes Market: Share of Cardiovascular Disorders, 2020-2030 (USD Million)
Figure 15.21 Prefilled Syringes Market: Share of Metabolic Disorders, 2020-2030 (Million Units)
Figure 15.22 Prefilled Syringes Market: Share of Metabolic Disorders, 2020-2030 (USD Million)
Figure 15.23 Prefilled Syringes Market: Share of Ophthalmic Disorder, 2020-2030 (Million Units)
Figure 15.24 Prefilled Syringes Market: Share of Ophthalmic Disorders, 2020-2030 (USD Million)
Figure 15.25 Prefilled Syringes Market: Share of Orthopedic Disorders, 2020-2030 (Million Units)
Figure 15.26 Prefilled Syringes Market: Share of Orthopedic Disorders, 2020-2030 (USD Million)
Figure 15.28 Prefilled Syringes Market: Share of Other Diseases, 2020-2030 (Million Units)
Figure 15.29 Prefilled Syringes Market: Share of Other Diseases, 2020-2030 (USD Million)
Figure 15.30 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
Figure 15.31 Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.32 Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.33 Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.34 Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.35 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
Figure 15.36 Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.37 Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.38 Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.39 Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.40 Prefilled Syringes Market: Distribution by Type of Drug Molecule, 2020, 2025 and 2030 (USD Million)
Figure 15.41 Prefilled Syringes Market: Share of Antibodies, 2020-2030 (Million Units)
Figure 15.42 Prefilled Syringes Market: Share of Antibodies, 2020-2030 (USD Million)
Figure 15.43 Prefilled Syringes Market: Share of Proteins, 2020-2030 (Million Units)
Figure 15.44 Prefilled Syringes Market: Share of Proteins, 2020-2030 (USD Million)
Figure 15.45 Prefilled Syringes Market: Share of Peptides, 2020-2030 (Million Units)
Figure 15.46 Prefilled Syringes Market: Share of Peptides, 2020-2030 (USD Million)
Figure 15.47 Prefilled Syringes Market: Share of Small Molecules, 2020-2030 (Million Units)
Figure 15.48 Prefilled Syringes Market: Share of Small Molecules, 2020-2030 (USD Million)
Figure 15.49 Prefilled Syringes Market: Share of Vaccines, 2020-2030 (Million Units)
Figure 15.50 Prefilled Syringes Market: Share of Vaccines, 2020-2030 (USD Million)
Figure 15.51 Prefilled Syringes Market: Distribution by Geographical Regions (USD Million)
Figure 15.52 Prefilled Syringes Market: Share of North America, 2020-2030 (Million Units)
Figure 15.53 Prefilled Syringes Market: Share of North America, 2020-2030 (USD Million)
Figure 15.54 Prefilled Syringes Market: Share of Europe, 2020-2030 (Million Units)
Figure 15.55 Prefilled Syringes Market: Share of Europe, 2020-2030 (USD Million)
Figure 15.56 Prefilled Syringes Market: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.57 Prefilled Syringes Market: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.58 Prefilled Syringes Market: Share of Latin America, 2020-2030 (Million Units)
Figure 15.59 Prefilled Syringes Market: Share of Latin America, 2020-2030 (USD Million)
Figure 15.60 Prefilled Syringes Market: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.61 Prefilled Syringes Market: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.62 Prefilled Syringes Market: Distribution by Specialty Syringes, 2020-2030 (Million Units)
Figure 15.63 Prefilled Syringes Market: Distribution by Specialty Syringes, 2020-2030 (USD Million)
Figure 15.64 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.65 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.66 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.67 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.68 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.69 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.70 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.71 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.72 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, 2020-2030 (Million Units)
Figure 15.73 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, 2020-2030 (USD Million)
Figure 15.74 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, 2020-2030 (Million Units)
Figure 15.75 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, 2020-2030 (USD Million)
Figure 15.76 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.77 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.78 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.79 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.80 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.81 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.82 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.83 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.84 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.85 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.86 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.87 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.88 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.89 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.90 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.91 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.92 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.93 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.94 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, 2020-2030 (Million Units)
Figure 15.95 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, 2020-2030 (USD Million)
Figure 15.96 Prefilled Syringes Market for Infectious Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.97 Prefilled Syringes Market for Infectious Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.98 Prefilled Syringes Market for Infectious Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.99 Prefilled Syringes Market for Infectious Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.100 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.101 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.102 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.103 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.104 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.105 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.106 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.107 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.108 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.109 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.110 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.111 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.112 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.113 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.114 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, 2020-2030 (Million Units)
Figure 15.115 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, 2020-2030 (USD Million)
Figure 15.116 Prefilled Syringes Market for Neurological Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.117 Prefilled Syringes Market for Neurological Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.118 Prefilled Syringes Market for Neurological Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.119 Prefilled Syringes Market for Neurological Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.120 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.122 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.123 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.124 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.125 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.126 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.127 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.128 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.129 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.130 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.131 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.132 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.133 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.134 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.135 Prefilled Syringes Market for Blood Disorders: Share of Proteins, 2020-2030 (Million Units)
Figure 15.136 Prefilled Syringes Market for Blood Disorders: Share of Proteins, 2020-2030 (USD Million)
Figure 15.137 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, 2020-2030 (Million Units)
Figure 15.138 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, 2020-2030 (USD Million)
Figure 15.139 Prefilled Syringes Market for Blood Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.140 Prefilled Syringes Market for Blood Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.141 Prefilled Syringes Market for Blood Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.142 Prefilled Syringes Market for Blood Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.143 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.144 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.145 Prefilled Syringes Market for Blood Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.146 Prefilled Syringes Market for Blood Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.147 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.148 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.149 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.150 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.151 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.152 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.153 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.154 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.155 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.156 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.157 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, 2020-2030 (Million Units)
Figure 15.158 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, 2020-2030 (USD Million)
Figure 15.159 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, 2020-2030 (Million Units)
Figure 15.160 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, 2020-2030 (USD Million)
Figure 15.161 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, 2020-2030 (Million Units)
Figure 15.162 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, 2020-2030 (USD Million)
Figure 15.163 Prefilled Syringes Market for Oncological Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.164 Prefilled Syringes Market for Oncological Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.165 Prefilled Syringes Market for Oncological Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.166 Prefilled Syringes Market for Oncological Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.167 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.168 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.169 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.170 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.171 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.172 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.173 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.174 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.175 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.176 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.177 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.178 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.179 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.180 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.181 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, 2020-2030 (Million Units)
Figure 15.182 Prefilled Syringes Market for Metabolic Disorders: Share of Peptides, 2020-2030 (USD Million)
Figure 15.183 Prefilled Syringes Market for Metabolic Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.185 Prefilled Syringes Market for Metabolic Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.186Prefilled Syringes Market for Metabolic Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.187 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.188 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.190 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.191 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.192 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.193 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.194 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 15.195 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.196 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.197 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.198 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.199 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.200 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.201 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (Million Units)
Figure 15.202 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, 2020-2030 (USD Million)
Figure 15.203 Prefilled Syringes Market for Other Disorders: Share of Antibodies, 2020-2030 (Million Units)
Figure 15.204 Prefilled Syringes Market for Other Disorders: Share of Antibodies, 2020-2030 (USD Million)
Figure 15.205 Prefilled Syringes Market for Other Disorders: Share of Peptide, 2020-2030 (Million Units)
Figure 15.206 Prefilled Syringes Market for Other Disorders: Share of Peptide, 2020-2030 (USD Million)
Figure 15.207 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, 2020-2030 (Million Units)
Figure 15.208 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, 2020-2030 (USD Million)
Figure 15.209 Prefilled Syringes Market for Other Disorders: Share of North America, 2020-2030 (Million Units)
Figure 15.210 Prefilled Syringes Market for Other Disorders: Share of North America, 2020-2030 (USD Million)
Figure 15.211 Prefilled Syringes Market for Other Disorders: Share of Europe, 2020-2030 (Million Units)
Figure 15.212 Prefilled Syringes Market for Other Disorders: Share of Europe, 2020-2030 (USD Million)
Figure 15.213 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, 2020-2030 (Million Units)
Figure 15.214 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, 2020-2030 (USD Million)
Figure 15.215 Prefilled Syringes Market for Other Disorders: Share of Latin America, 2020-2030 (Million Units)
Figure 15.216 Prefilled Syringes Market for Other Disorders: Share of Latin America, 2020-2030 (USD Million)
Figure 15.217 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, 2020-2030 (Million Units)
Figure 15.218 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, 2020-2030 (USD Million)
Figure 16.1 Diabetes: Country Wise Distribution of Prevalence and Mortality, 2017
Figure 16.2 FDA Approved Biologics, 2009-2019
Figure 16.3 Top Selling Biologics: Estimated Patent Expiry
Figure 17.1 SWOT Analysis
Figure 17.2Prefilled Syringe Recalls: Distribution by Type of Concern, 2003-2019
Figure 17.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 18.1 AptarGroup: Annual Revenues, 2013 - H1 2019 (USD Billion)
Figure 18.2 Datwyler Group: Annual Revenues, 2013 - H12019 (CHF Million)
Figure 18.3 Sumitomo Rubber Industries: Annual Revenues, 2013 - H1 2019 (JPY Billion)
Figure 18.4 Sumitomo Rubber Industries: Revenue Distribution by Business Segment, 2018
Figure 19.1 Prefilled Syringe: Fill / Finish Process
Figure 19.2 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 19.3 Prefilled Syringe Fill / Finish Service Providers: Distribution by Scale of Operation 
Figure 19.4 Prefilled Syringe Fill / Finish Service Providers: Distribution by Geographical Location of Headquarters and Type of Drug Molecule 
Figure 20.1 Elcam Medical: Product Portfolio
Figure 20.2 Elcam Medical: Flexi-Q Autoinjectors
Figure 20.3 Flexi-Q PFS: Components
Figure 20.4 Flexi-Q PFS: Mechanism of Drug Delivery
Figure 20.5 Flexi-Q DV: Components
Figure 20.6 Flexi-Q DV: Mechanism of Drug Delivery
Figure 20.7 Flexi-Q mMU: Components
Figure 20.8 Flexi-Q eMU: Components
Figure 20.9 Flexi-Q mMU / Flexi-Q eMU: Mechanism of Drug Delivery
Figure 20.10 Flexi-Q EAI: Mechanism of Drug Delivery
Figure 20.11 Owen Mumford: Product Portfolio
Figure 20.12 Autoject Micro: Mechanism of Drug Delivery 
Figure 20.13 Autoject 2 Autoinjector: Mechanism of Drug Delivery
Figure 20.14 Autoject Mini: Mechanism of Drug Delivery
Figure 20.15 SHL Medical: Product Portfolio
Figure 20.16 SHL Medical:  Prefilled Syringe-based Autoinjectors
Figure 20.17 SHL Medical:  Cartridge-based Autoinjectors
Figure 20.18 SHL Medical: Two-Step Autoinjectors
Figure 20.19 SHL Medical Two-Step Autoinjectors: Mechanism of Drug Delivery
Figure 20.20 Union Medico: 45˚ Autoinjector Portfolio
Figure 20.21 Union Medico: Parts of 45˚/R Autoinjector
Figure 20.22 Union Medico: Types of 45˚/R Autoinjector
Figure 20.23 Union Medico: Types of 90˚ Autoinjectors
Figure 20.24 Exclusive: Components
Figure 20.25 Ypsomed: Annual Revenues, FY 2014-15- FY 2018-19 (CHF Million)
Figure 20.26 Ypsomed: Sales by Business Divisions, FY 2018-19 (CHF Million, %)
Figure 20.27 Ypsomed: Product Portfolio
Figure 20.28 YpsoMate: Mechanism of Drug Delivery 
Figure 20.29 VarioJect: Mechanism of Drug Delivery

List Of Tables

Table 3.1 Drugs: Shifted from Vials to Prefilled Syringe Systems 
Table 3.2 Components of Prefilled Syringes
Table 3.3 Classification of Prefilled Syringes
Table 3.4 Advantages of Glass as Barrel Fabrication Material
Table 3.5 Glass Barrel Prefilled Syringe Recalls
Table 3.6 Advantages of Plastic Polymers as Barrel Fabrication Material
Table 3.7 Pharmaceutical Filling Lines: Steps Performed by Type of Packaging of Prefilled Syringe 
Table 4.1 Prefilled Syringes: List of Available / Under Development Devices 
Table 4.2 Prefilled Syringes: List of Developers
Table 6.1 Key Manufacturers of Prefilled Syringes
Table 6.2 Becton Dickinson: Future Outlook
Table 6.3 West Pharmaceutical: Features of Daikyo Crystal Zenith Prefilled Syringe
Table 6.4 West Pharmaceutical: Future Outlook
Table 6.5 Gerresheimer: Features of Gx Glass Prefilled Syringe 
Table 6.6 Gerresheimer: Features of ClearJect Prefilled Syringe 
Table 6.7 Gerresheimer: Future Outlook
Table 6.8 Ompi: Features of EZ-Fill Fina Prefilled Syringe 
Table 6.9 Ompi: Features of EZ-Fill Nexa Prefilled Syringe
Table 6.10 Ompi: Features of EZ-Fill Alba Prefilled Syringe
Table 6.11 Ompi: Future Outlook
Table 6.12 SCHOTT: Features of syriQ Prefilled Syringe 
Table 6.13 SCHOTT: Features of TopPac Prefilled Syringe
Table 6.14 SCHOTT: Future Outlook
Table 6.15 Nipro: Features of Prefilled Syringe 
Table 6.16 Nipro: Future Outlook
Table 6.17 Weigao: Features of WeGo Glass Prefilled Syringe 
Table 6.18 Taisei Kako: Features of VF-Syringes
Table 6.19 Taisei Kako: Features of SIN-Syringes
Table 6.20 Taisei Kako: Features of ClearJect Prefilled Syringes 
Table 6.21 Taisei Kako: Features of FULJECT Passive Type Syringes
Table 6.22 Terumo: Future Outlook
Table 6.23 Shandong Zibo: Features of Prefilled Syringes
Table 6.24Vetter Pharma: Features of Lyo-Ject Glass Prefilled Syringe
Table 7.1 Add-On Safety Device Manufacturers
Table 7.2 Integrated Prefilled Safety Device Manufacturers 
Table 8.1 US FDA Center for Drug and Device Approval
Table 8.2 Regulatory Review Timelines in the US
Table 8.3 Regulatory Bodies in EU5 Countries
Table 8.4 Device Classification: Japan
Table 8.5 Regulatory Review Timelines in Saudi Arabia
Table 9.1 Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2019
Table 9.2 Prefilled Syringe Combination Products: Information on Approval Years and Geographies, 2013-2019
Table 9.3 Prefilled Syringe Combination Products: Information on Dosage Strength
Table 9.4 Prefilled Syringe Combination Products: List of Other Drug Delivery Solutions, 2013-2019
Table 9.5 Prefilled Syringe Combination Products: List of Clinical Stage Drugs, 2013-2019
Table 9.6 Prefilled Syringe Combination Products: List of Developers
Table 9.7 Other Drugs Sold in Prefilled Syringes
Table 10.1 Autoimmune Disorders: Leading Approved Drugs 
Table 10.2 Autoimmune Disorders: Approved Drugs Available in Prefilled Syringes
Table 10.3 Autoimmune Disorders: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development 
Table 10.4 Infectious Diseases: Leading Antiviral Drugs
Table 10.5 Infectious Diseases: Antiviral Drugs Available in Prefilled Syringes
Table 10.6 Infectious Diseases: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development 
Table 10.7 Infectious Diseases: Leading Vaccines 
Table 10.8 Infectious Diseases: Vaccines Available in Prefilled Syringes 
Table 10.9 Neurological Disorders: Leading Drugs 
Table 10.10 Neurological Disorders: Approved Drugs Available in Prefilled Syringes 
Table 10.11 Neurological Disorders: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development 
Table 10.12 Metabolic Disorders: Leading Diabetes Drugs 
Table 10.13 Metabolic Disorders: Approved Drugs Available in Prefilled Insulin Pen 
Table 10.14 Metabolic Disorders: Prefilled Syringe Approved Drugs Patent Expiry and Biosimilar Development 
Table 11.1 Marketed Drugs: Most Likely Candidates for Delivery via Prefilled Syringes
Table 11.2 Marketed Drugs: Likely Candidates for Delivery via Prefilled Syringes
Table 11.3 Marketed Drugs: Less Likely Candidates for Delivery via Prefilled Syringes
Table 11.4 Marketed Drugs: Least Likely Candidates for Delivery via Prefilled Syringes
Table 11.5 Clinical Stage Drug Candidates: Most Likely Candidates for Delivery via Prefilled Syringes
Table 11.6 Clinical Stage Drug Candidates: Likely Candidates for Delivery via Prefilled Syringes
Table 11.7 Clinical Stage Drug Candidates: Less Likely Candidates for Delivery via Prefilled Syringes
Table 11.8 Clinical Stage Drug Candidates: Least Likely Candidates for Delivery via Prefilled Syringes
Table 11.9 Opportunities in North America: Most Likely Partners for Prefilled Syringe Combination Product Development
Table 11.10 Opportunities in North America: Likely Partners for Prefilled Syringe Combination Product Development
Table 11.11 Opportunities in North America: Less Likely Partners for Prefilled Syringe Combination Product Development
Table 11.12 Opportunities in North America: Least Likely Partners for Prefilled Syringe Combination Product Development
Table 11.13 Opportunities in Europe: Most Likely Partners for Prefilled Syringe Combination Product Development
Table 11.14 Opportunities in Europe: Likely Partners for Prefilled Syringe Combination Product Development
Table 11.15 Opportunities in Europe: Less Likely Partners for Prefilled Syringe Combination Product Development
Table 11.16 Opportunities in Europe: Least Likely Partners for Prefilled Syringe Combination Product Development
Table 11.17 Opportunities in Asia-Pacific and Rest of the World: Most Likely Partners Prefilled Syringe Combination Product Development
Table 11.18 Opportunities in Asia-Pacific and Rest of the World: Likely Partners for Prefilled Syringe Combination Product Development
Table 11.19 Opportunities in Asia-Pacific and Rest of the World: Less Likely Partners Prefilled Syringe Combination Product Development
Table 11.20 Opportunities in Asia-Pacific and Rest of the World: Least Likely Partners Prefilled Syringe Combination Product Development
Table 13.1 Prefilled Flush Syringes Available in the Market
Table 13.2 Drugs Available with Prefilled Diluent Syringe Systems 
Table 13.3 Contrast Agents Available in Prefilled Syringes 
Table 14.1Dual / Multi-Chamber Prefilled Syringes
Table 14.2Drugs Marketed in Dual / Multi-Chamber Prefilled Syringes
Table 15.1Therapeutic Areas: Relative Share of Approved and Clinical Products with Prefilled Syringes
Table 16.1 Fraction of Global Population above 60 years (in Millions), 2017, 2030 and 2050
Table 16.2 Autoinjector Approvals, 2016-2019
Table 16.3 Marketed Autoinjectors / Pen Injectors with Prefilled Syringes
Table 17.1 List of Marketed/Pipeline Needleless Injection Devices
Table 17.2 Prefilled Syringe Recalls, 2003-2019
Table 18.1 Prefilled Syringe Component Manufacturers: List of Elastomeric Component Providers
Table 18.2 Prefilled Syringes Elastomeric Container Closure Providers: List of Companies Profiled 
Table 18.3 AptarGroup: Company Overview
Table 18.4 Aptar Pharma: Product Details
Table 18.5 AptarGroup: Recent Developments and Future Outlook
Table 18.6 West Pharmaceutical: Company Overview
Table 18.7 West Pharmaceutical: Product Details
Table 18.8 Datwyler Sealing Solutions (Datwyler Group): Company Overview
Table 18.9 Datwyler Sealing Solutions (Datwyler Group): Product Details
Table 18.10 Datwyler Sealing Solutions (Datwyler Group): Recent Developments and Future Outlook
Table 18.11 Lonstroff: Company Overview
Table 18.12 Sumitomo Rubber Industries: Company Overview
Table 18.13 Lonstroff: Product Details
Table 18.14 Sumitomo Rubber Industries: Recent Developments and Future Outlook
Table 18.15 Ompi (Stevanato Group): Company Overview
Table 18.16 Ompi (Stevanato Group): Product Details
Table 18.17 Jiangsu Hualan Pharmaceutical New Material: Company Overview
Table 18.18 Jiangsu Hualan Pharmaceutical New Material: Product Details
Table 19.1 List of Fill / Finish Service Providers
Table 20.1 List of Autoinjector Devices (Using Prefilled Syringes)
Table 20.2 YpsoMate Autoinjectors: Dimensions of Prefilled Syringes 
Table 21.1 Prefilled Syringes Market: Key Takeaways
Table 22.1 Oval Medical Technologies: Key Highlights 
Table 22.2 Intas Pharmaceuticals: Key Highlights 
Table 22.3 IDT Biologika: Key Highlights 
Table 22.4 West Pharmaceutical: Key Highlights 
Table 22.5 Lonstroff: Key Highlights 
Table 23.1 Prefilled Syringes: Distribution by Type of Barrel Fabrication Material
Table 23.2 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 23.3 Prefilled Syringes: Distribution by Type of Needle System
Table 23.4 Prefilled Syringes: Distribution by Device Capacity
Table 23.5 Prefilled Syringe Developers: Distribution by Year of Establishment
Table 23.6 Prefilled Syringe Developers: Distribution by Company Size
Table 23.7 Prefilled Syringe Developers: Distribution by Geographical Location of Headquarters
Table 23.8 Prefilled Syringe Developers: Distribution by Geographical Location of Manufacturing Facilities
Table 23.9 BD Medical: Annual Revenues, FY 2011 - FY 2018 (USD Billion)
Table 23.10 BD Medical: Revenue Distribution by Sub-Segments, FY 2018 (USD Billion)
Table 23.11 West Pharmaceutical: Annual Revenues, 2011-H1 2019 (USD Million)
Table 23.12 West Pharmaceutical: Revenue Distribution by Business Segments, 2018 (USD Million)
Table 23.13 West Pharmaceutical: Revenue Distribution by Region 2018 (USD Million)
Table 23.14 Gerresheimer: Annual Revenues, 2011-H1 2019 (EUR Million)
Table 23.15 Gerresheimer: Revenue Distribution by Business Divisions, FY 2018 (EUR Million)
Table 23.16 Gerresheimer: Revenue Distribution by Region, FY 2018 (EUR Million)
Table 23.17 Schott: Annual Revenues, FY 2013-FY 2018 (EUR Million)
Table 23.18 Schott: Revenue Distribution by Geography, FY 2018 (EUR Million)
Table 23.19 Nipro: Annual Revenues, FY 2012 – FY 2019 (JPY Billion)
Table 23.20 Nipro: Revenue Distribution by Business Divisions, FY 2019(JPY Billion)
Table 23.21 Nipro: Revenue Distribution by Region, FY 2019 (JPY Billion)
Table 23.22 Weigao: Annual Revenues, 2016-H12019 (RMB Billion)
Table 23.23 Weigao: Revenue Distribution by Principle Products, H1 2019 (RMB Million)
Table 23.24 Terumo: Annual Revenues, FY 2012 - FY 2019 (JPY Billion)
Table 23.25 Terumo: Revenue Distribution by Business Divisions, FY 2018 (JPY Billion)
Table 23.26 Terumo: Revenue Distribution by Region, FY 2018 (JPY Billion)
Table 23.27 Approved Prefilled Syringe Combination Products: Distribution by Type of Drug Molecule
Table 23.28 Approved Prefilled Syringe Combination Products: Distribution by Approval Year
Table 23.29 Approved Prefilled Syringe Combination Products: Distribution by Approval Geographies
Table 23.30 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Table 23.31 Approved Prefilled Syringe Combination Products: Distribution by Target Therapeutic Area
Table 23.32 Approved Prefilled Syringe Combination Products: Distribution by Other Dosage Forms
Table 23.33 Pipeline Prefilled Syringes Combination Products: Distribution by Type of Drug
Table 23.34 Pipeline Prefilled Syringes Combination Products: Distribution by Phase of Development
Table 23.35 Pipeline Prefilled Syringes Combination Products: Distribution by Route of Administration
Table 23.36 Pipeline Prefilled Syringes Combination Products: Distribution by Target Therapeutic Area
Table 23.37 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Table 23.38 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Table 23.39 Prefilled Syringe Combination Product Developers: Distribution by Geographical Location of Headquarters
Table 23.40 HUMIRA®: Annual Sales, 2003-H1 2019 (USD Million)
Table 23.41 Enbrel®: Annual Sales in the US and Canada, 2002-H1 2019 (USD Million)
Table 23.42 Enbrel®: Annual Sales Outside the US and Canada, 2002-H1 2019 (USD Million)
Table 23.43 Prefilled Syringe Prices, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Table 23.44 Global Prefilled Syringes Market, Conservative Scenario, 2020-2030 (Million Units)
Table 23.45 Global Prefilled Syringes Market, Base Scenario, 2020-2030 (Million Units)
Table 23.46 Global Prefilled Syringes Market, Optimistic Scenario, 2019-2030 (Million Units)
Table 23.47 Global Prefilled Syringes Market, Conservative Scenario, 2020-2030 (USD Million)
Table 23.48 Global Prefilled Syringes Market, Base Scenario, 2020-2030 (USD Million)
Table 23.49 Global Prefilled Syringes Market, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.50 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.51 Prefilled Syringes Market: Share of Autoimmune Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.52 Prefilled Syringes Market: Share of Autoimmune Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.53 Prefilled Syringes Market: Share of Autoimmune Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.54 Prefilled Syringes Market: Share of Autoimmune Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.55 Prefilled Syringes Market: Share of Autoimmune Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.56 Prefilled Syringes Market: Share of Infectious Diseases, Conservative Scenario, 2020-2030 (Million Units)
Table 23.57 Prefilled Syringes Market: Share of Infectious Diseases, Base Scenario, 2020-2030 (Million Units)
Table 23.58 Prefilled Syringes Market: Share of Infectious Diseases, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.59 Prefilled Syringes Market: Share of Infectious Diseases, Conservative Scenario, 2020-2030 (USD Million)
Table 23.60 Prefilled Syringes Market: Share of Infectious Diseases, Base Scenario, 2020-2030 (USD Million)
Table 23.61 Prefilled Syringes Market: Share of Infectious Diseases, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.62 Prefilled Syringes Market: Share of Neurological Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.63 Prefilled Syringes Market: Share of Neurological Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.64 Prefilled Syringes Market: Share of Neurological Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.65 Prefilled Syringes Market: Share of Neurological Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.66 Prefilled Syringes Market: Share of Neurological Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.67 Prefilled Syringes Market: Share of Neurological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.68 Prefilled Syringes Market: Share of Blood Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.69 Prefilled Syringes Market: Share of Blood Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.70 Prefilled Syringes Market: Share of Blood Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.71 Prefilled Syringes Market: Share of Blood Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.72 Prefilled Syringes Market: Share of Blood Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.73 Prefilled Syringes Market: Share of Blood Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.74 Prefilled Syringes Market: Share of Oncological Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.75 Prefilled Syringes Market: Share of Oncological Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.76 Prefilled Syringes Market: Share of Oncological Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.77 Prefilled Syringes Market: Share of Oncological Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.78 Prefilled Syringes Market: Share of Oncological Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.79 Prefilled Syringes Market: Share of Oncological Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.80 Prefilled Syringes Market: Share of Psychiatric Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.81 Prefilled Syringes Market: Share of Psychiatric Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.82 Prefilled Syringes Market: Share of Psychiatric Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.83 Prefilled Syringes Market: Share of Psychiatric Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.84 Prefilled Syringes Market: Share of Psychiatric Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.85 Prefilled Syringes Market: Share of Psychiatric Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.86 Prefilled Syringes Market: Share of Respiratory Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.87 Prefilled Syringes Market: Share of Respiratory Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.88 Prefilled Syringes Market: Share of Respiratory Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.89 Prefilled Syringes Market: Share of Respiratory Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.90 Prefilled Syringes Market: Share of Respiratory Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.91 Prefilled Syringes Market: Share of Respiratory Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.92 Prefilled Syringes Market: Share of Cardiovascular Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.93 Prefilled Syringes Market: Share of Cardiovascular Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.94 Prefilled Syringes Market: Share of Cardiovascular Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.95 Prefilled Syringes Market: Share of Cardiovascular Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.96 Prefilled Syringes Market: Share of Cardiovascular Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.97 Prefilled Syringes Market: Share of Cardiovascular Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.98 Prefilled Syringes Market: Share of Metabolic Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.99 Prefilled Syringes Market: Share of Metabolic Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.100 Prefilled Syringes Market: Share of Metabolic Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.101 Prefilled Syringes Market: Share of Metabolic Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.102 Prefilled Syringes Market: Share of Metabolic Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.103 Prefilled Syringes Market: Share of Metabolic Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.104 Prefilled Syringes Market: Share of Ophthalmic Diseases, Conservative Scenario, 2020-2030 (Million Units)
Table 23.105 Prefilled Syringes Market: Share of Ophthalmic Diseases, Base Scenario, 2020-2030 (Million Units)
Table 23.106 Prefilled Syringes Market: Share of Ophthalmic Diseases, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.107 Prefilled Syringes Market: Share of Ophthalmic Diseases, Conservative Scenario, 2020-2030 (USD Million)
Table 23.108 Prefilled Syringes Market: Share of Ophthalmic Diseases, Base Scenario, 2020-2030 (USD Million)
Table 23.109 Prefilled Syringes Market: Share of Ophthalmic Diseases, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.110 Prefilled Syringes Market: Share of Orthopedic Disorders, Conservative Scenario, 2020-2030 (Million Units)
Table 23.111 Prefilled Syringes Market: Share of Orthopedic Disorders, Base Scenario, 2020-2030 (Million Units)
Table 23.112 Prefilled Syringes Market: Share of Orthopedic Disorders, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.113 Prefilled Syringes Market: Share of Orthopedic Disorders, Conservative Scenario, 2020-2030 (USD Million)
Table 23.114 Prefilled Syringes Market: Share of Orthopedic Disorders, Base Scenario, 2020-2030 (USD Million)
Table 23.115 Prefilled Syringes Market: Share of Orthopedic Disorders, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.116 Prefilled Syringes Market: Share of Other Diseases, Conservative Scenario, 2020-2030 (Million Units)
Table 23.117 Prefilled Syringes Market: Share of Other Diseases, Base Scenario, 2020-2030 (Million Units)
Table 23.118 Prefilled Syringes Market: Share of Other Diseases, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.119 Prefilled Syringes Market: Share of Other Diseases, Conservative Scenario, 2020-2030 (USD Million)
Table 23.120 Prefilled Syringes Market: Share of Other Diseases, Base Scenario, 2020-2030 (USD Million)
Table 23.121 Prefilled Syringes Market: Share of Other Diseases, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.122 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, Conservative Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.123 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, Base Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.124 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.125 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.126 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.127 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.128 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.129 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.130 Global Prefilled Syringes Market: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.131 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.132 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.133 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.134 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.135 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.136 Global Prefilled Syringes Market: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.137 Prefilled Syringes Market: Distribution by Type of Chamber System, Conservative Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.138 Prefilled Syringes Market: Distribution by Type of Chamber System, Base Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.139 Prefilled Syringes Market: Distribution by Type of Chamber System, Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.140 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.141 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.142 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.143 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.144 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.145 Global Prefilled Syringes Market: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.146 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.147 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.148 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.149 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.150 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.151 Global Prefilled Syringes Market: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.152 Prefilled Syringes Market: Distribution by Therapeutic Area, Conservative Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.153 Prefilled Syringes Market: Distribution by Therapeutic Area, Base Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.154 Prefilled Syringes Market: Distribution by Therapeutic Area, Optimistic Scenario, 2020, 2025 and 2030 (USD Million)
Table 23.155 Global Prefilled Syringes Market: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
Table 23.156 Global Prefilled Syringes Market: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
Table 23.157 Global Prefilled Syringes Market: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.158 Global Prefilled Syringes Market: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
Table 23.159 Global Prefilled Syringes Market: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
Table 23.160 Global Prefilled Syringes Market: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.161 Global Prefilled Syringes Market: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
Table 23.162 Global Prefilled Syringes Market: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
Table 23.163 Global Prefilled Syringes Market: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.164 Global Prefilled Syringes Market: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
Table 23.165 Global Prefilled Syringes Market: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
Table 23.166 Global Prefilled Syringes Market: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.167 Global Prefilled Syringes Market: Share of Peptides, Conservative Scenario, 2020-2030 (Million Units)
Table 23.168 Global Prefilled Syringes Market: Share of Peptides, Base Scenario, 2020-2030 (Million Units)
Table 23.169 Global Prefilled Syringes Market: Share of Peptides, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.170 Global Prefilled Syringes Market: Share of Peptides, Conservative Scenario, 2020-2030 (USD Million)
Table 23.171 Global Prefilled Syringes Market: Share of Peptides, Base Scenario, 2020-2030 (USD Million)
Table 23.172 Global Prefilled Syringes Market: Share of Peptides, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.173 Global Prefilled Syringes Market: Share of Small Molecules, Conservative Scenario, 2020-2030 (Million Units)
Table 23.174 Global Prefilled Syringes Market: Share of Small Molecules, Base Scenario, 2020-2030 (Million Units)
Table 23.175 Global Prefilled Syringes Market: Share of Small Molecules, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.176 Global Prefilled Syringes Market: Share of Small Molecules, Conservative Scenario, 2020-2030 (USD Million)
Table 23.177 Global Prefilled Syringes Market: Share of Small Molecules, Base Scenario, 2020-2030 (USD Million)
Table 23.178 Global Prefilled Syringes Market: Share of Small Molecules, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.179 Global Prefilled Syringes Market: Share of Vaccines, Conservative Scenario, 2020-2030 (Million Units)
Table 23.180 Global Prefilled Syringes Market: Share of Vaccines, Base Scenario, 2020-2030 (Million Units)
Table 23.181 Global Prefilled Syringes Market: Share of Vaccines, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.182 Global Prefilled Syringes Market: Share of Vaccines, Conservative Scenario, 2020-2030 (USD Million)
Table 23.183 Global Prefilled Syringes Market: Share of Vaccines, Base Scenario, 2020-2030 (USD Million)
Table 23.184 Global Prefilled Syringes Market: Share of Vaccines, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.185 Global Prefilled Syringes Market: Distribution by North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.186 Global Prefilled Syringes Market: Distribution by North America, Base Scenario, 2020-2030 (Million Units)
Table 23.187 Global Prefilled Syringes Market: Distribution by North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.188 Global Prefilled Syringes Market: Distribution by North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.189 Global Prefilled Syringes Market: Distribution by North America, Base Scenario, 2020-2030 (USD Million)
Table 23.190 Global Prefilled Syringes Market: Distribution by North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.191 Global Prefilled Syringes Market: Distribution by Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.192 Global Prefilled Syringes Market: Distribution by Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.193 Global Prefilled Syringes Market: Distribution by Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.194 Global Prefilled Syringes Market: Distribution by Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.195 Global Prefilled Syringes Market: Distribution by Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.196 Global Prefilled Syringes Market: Distribution by Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.197 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.198 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.199 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.200 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.201 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.202 Global Prefilled Syringes Market: Distribution by Asia-Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.203 Global Prefilled Syringes Market: Distribution by Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.204 Global Prefilled Syringes Market: Distribution by Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.205 Global Prefilled Syringes Market: Distribution by Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.206 Global Prefilled Syringes Market: Distribution by Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.207 Global Prefilled Syringes Market: Distribution by Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.208 Global Prefilled Syringes Market: Distribution by Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.209 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.210 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.211 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.212 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.213 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.214 Global Prefilled Syringes Market: Distribution by Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.215 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.216 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.217 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.218 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.219 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.220 Global Prefilled Syringes Market: Distribution by Specialty Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.221 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.222 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.223 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.224 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.225 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.226 Prefilled Syringes Market for Autoimmune Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.227 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
Table 23.228 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.229 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.230 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.231 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.232 Prefilled Syringes Market for Autoimmune Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.233 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.234 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.235 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.236 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.237 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.238 Prefilled Syringes Market for Autoimmune Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.239 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.240 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.241 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.242 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.243 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.244 Prefilled Syringes Market for Autoimmune Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.245 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
Table 23.246 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
Table 23.247 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.248 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
Table 23.249 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
Table 23.250 Prefilled Syringes Market for Autoimmune Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.251 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
Table 23.252 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
Table 23.253 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.254 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
Table 23.255 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
Table 23.256 Prefilled Syringes Market for Autoimmune Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.257 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.258 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.259 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.260 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.261 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.262 Prefilled Syringes Market for Autoimmune Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.263 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.264 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.265 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.166 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.267 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.268 Prefilled Syringes Market for Autoimmune Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.269 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.270 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.271 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.272 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.273 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.274 Prefilled Syringes Market for Autoimmune Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.275 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.276 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.277 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.279 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.280 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.281 Prefilled Syringes Market for Autoimmune Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.282 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.283 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.284 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.285 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.286 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.287 Prefilled Syringes Market for Autoimmune Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.288 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.289 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.290 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.291 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.292 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.293 Prefilled Syringes Market for Infectious Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.294 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.295 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.296 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.297 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.298 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.299 Prefilled Syringes Market for Infectious Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.300 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.301 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.302 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.303 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.304 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.305 Prefilled Syringes Market for Infectious Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.306 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.307 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.308 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.309 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.310 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.311 Prefilled Syringes Market for Infectious Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.312 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Conservative Scenario, 2020-2030 (Million Units)
Table 23.313 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Base Scenario, 2020-2030 (Million Units)
Table 23.314 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.315 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Conservative Scenario, 2020-2030 (USD Million)
Table 23.316 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Base Scenario, 2020-2030 (USD Million)
Table 23.317 Prefilled Syringes Market for Infectious Disorders: Share of Vaccines, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.318 Prefilled Syringes Market for Infectious Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.319 Prefilled Syringes Market for Infectious Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.320 Prefilled Syringes Market for Infectious Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.321 Prefilled Syringes Market for Infectious Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.322 Prefilled Syringes Market for Infectious Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.323 Prefilled Syringes Market for Infectious Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.324 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.325 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.326 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.327 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.328 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.329 Prefilled Syringes Market for Infectious Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.330 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.331 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.332 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.333 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.334 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.335 Prefilled Syringes Market for Infectious Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.336 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.337 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.338 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.339 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.340 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.341 Prefilled Syringes Market for Infectious Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.342 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.343 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.344 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.345 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.346 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.347 Prefilled Syringes Market for Infectious Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.348 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.349 Prefilled Syringes Market for Neurological e Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.350 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.351 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.352 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.353 Prefilled Syringes Market for Neurological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.354 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
Table 23.355 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.356 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.357 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.358 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.359 Prefilled Syringes Market for Neurological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.360 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.361 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.362 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.363 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.365 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.366 Prefilled Syringes Market for Neurological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.367 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.368 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.369 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 370 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.371 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.372 Prefilled Syringes Market for Neurological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.373 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
Table 23.374 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
Table 23.375 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.376 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
Table 23.377 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
Table 23.378 Prefilled Syringes Market for Neurological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.379 Prefilled Syringes Market for Neurological Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.380 Prefilled Syringes Market for Neurological Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.381 Prefilled Syringes Market for Neurological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.382 Prefilled Syringes Market for Neurological Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.383 Prefilled Syringes Market for Neurological Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.384 Prefilled Syringes Market for Neurological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.385 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.386 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.387 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.388 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.389 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.390 Prefilled Syringes Market for Neurological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.391 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.392 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.393 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.394 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.395 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.396 Prefilled Syringes Market for Neurological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.399 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.400 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.401 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.402 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.403 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.404 Prefilled Syringes Market for Neurological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.405 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.406 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.407 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.408 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.409 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.410 Prefilled Syringes Market for Neurological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.411 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.412 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.413 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.414 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.415 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.416 Prefilled Syringes Market for Blood Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.417 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
Table 23.418 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.419 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.420 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.421 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.422 Prefilled Syringes Market for Blood Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.423 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.424 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.425 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.426 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.427 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.428 Prefilled Syringes Market for Blood Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.429 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.430 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.431 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.432 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.433 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.434 Prefilled Syringes Market for Blood Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.435 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
Table 23.436 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
Table 23.437 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.438 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
Table 23.439 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
Table 23.440 Prefilled Syringes Market for Blood Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.441 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (Million Units)
Table 23.442 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (Million Units)
Table 23.443 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.444 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (USD Million)
Table 23.445 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (USD Million)
Table 23.446 Prefilled Syringes Market for Blood Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.447 Prefilled Syringes Market for Blood Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.448 Prefilled Syringes Market for Blood Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.449 Prefilled Syringes Market for Blood Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.450 Prefilled Syringes Market for Blood Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.451 Prefilled Syringes Market for Blood Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.452 Prefilled Syringes Market for Blood Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.453 Prefilled Syringes Market for Blood Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.454 Prefilled Syringes Market for Blood Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.455 Prefilled Syringes Market for Blood Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.456 Prefilled Syringes Market for Blood Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.457 Prefilled Syringes Market for Blood Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.458 Prefilled Syringes Market for Blood Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.459 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.460 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.461 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.462 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.463 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.464 Prefilled Syringes Market for Blood Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.465 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.466 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.469 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.470 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.471 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.472 Prefilled Syringes Market for Blood Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.473 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.474 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.475 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.476 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.477 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.478 Prefilled Syringes Market for Blood Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.479 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.480 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.481 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.482 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.483 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.484 Prefilled Syringes Market for Oncological Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.485 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
Table 23.486 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.487 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.488 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.489 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.490 Prefilled Syringes Market for Oncological Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.491 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.492 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.493 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.494 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.496 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.497 Prefilled Syringes Market for Oncological Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.498 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.499 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.500 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.501 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.502 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.503 Prefilled Syringes Market for Oncological Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.504 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
Table 23.505 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
Table 23.506 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.507 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
Table 23.508 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
Table 23.509 Prefilled Syringes Market for Oncological Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.510 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (Million Units)
Table 23.511 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Base Scenario, 2020-2030 (Million Units)
Table 23.512 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.513 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Conservative Scenario, 2020-2030 (USD Million)
Table 23.514 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Base Scenario, 2020-2030 (USD Million)
Table 23.515 Prefilled Syringes Market for Oncological Disorders: Share of Proteins, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.516 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (Million Units)
Table 23.517 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Base Scenario, 2020-2030 (Million Units)
Table 23.518 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.519 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (USD Million)
Table 23.520 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Base Scenario, 2020-2030 (USD Million)
Table 23.521 Prefilled Syringes Market for Oncological Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.522 Prefilled Syringes Market for Oncological Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.523 Prefilled Syringes Market for Oncological Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.524 Prefilled Syringes Market for Oncological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.525 Prefilled Syringes Market for Oncological Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.526 Prefilled Syringes Market for Oncological Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.527 Prefilled Syringes Market for Oncological Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.528 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.529 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.530 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.531 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.532 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.533 Prefilled Syringes Market for Oncological Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.534 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.535 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.536 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.537 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.538 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.539 Prefilled Syringes Market for Oncological Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.540 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.541 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.542 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.543 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.544 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.545 Prefilled Syringes Market for Oncological Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.546 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.547 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.548 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.549 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.550 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.551 Prefilled Syringes Market for Oncological Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.552 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.553 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.554 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.555 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.556 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.557 Prefilled Syringes Market for Metabolic Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.558 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
Table 23.559 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.560 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.561 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.562 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.563 Prefilled Syringes Market for Metabolic Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.564 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.565 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.566 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.567 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.568 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.569 Prefilled Syringes Market for Metabolic Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.570 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.571 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.572 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.573 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.573 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.575 Prefilled Syringes Market for Metabolic Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.576 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (Million Units)
Table 23.577 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Base Scenario, 2020-2030 (Million Units)
Table 23.578 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.579 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (USD Million)
Table 23.580 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Base Scenario, 2020-2030 (USD Million)
Table 23.581 Prefilled Syringes Market for Metabolic Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.582 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.583 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.584 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.585 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.586 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.587 Prefilled Syringes Market for Metabolic Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.588 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.589 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.590 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.591 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.592 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.593 Prefilled Syringes Market for Metabolic Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.594 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.595 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.596 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.597 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.598 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.599 Prefilled Syringes Market for Metabolic Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.600 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.601 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.602 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.603 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.604 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.605 Prefilled Syringes Market for Metabolic Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.606 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.607 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.608 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.609 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.610 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.612 Prefilled Syringes Market for Metabolic Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.613 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.614 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.615 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.616 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.617 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.618 Prefilled Syringes Market for Other Disorders: Share of Glass Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.619 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario 2020-2030 (Million Units)
Table 23.620 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.621 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.622 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.623 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.624 Prefilled Syringes Market for Other Disorders: Share of Plastic Barrel Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.625 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.626 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.627 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.628 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.629 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.630 Prefilled Syringes Market for Other Disorders: Share of Single Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.631 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (Million Units)
Table 23.632 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (Million Units)
Table 23.633 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.634 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Conservative Scenario, 2020-2030 (USD Million)
Table 23.635 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Base Scenario, 2020-2030 (USD Million)
Table 23.636 Prefilled Syringes Market for Other Disorders: Share of Dual Chamber Prefilled Syringes, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.637 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (Million Units)
Table 23.638 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Base Scenario, 2020-2030 (Million Units)
Table 23.639 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.640 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Conservative Scenario, 2020-2030 (USD Million)
Table 23.641 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Base Scenario, 2020-2030 (USD Million)
Table 23.642 Prefilled Syringes Market for Other Disorders: Share of Antibodies, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.643 Prefilled Syringes Market for Other Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (Million Units)
Table 23.644 Prefilled Syringes Market for Other Disorders: Share of Peptide, Base Scenario, 2020-2030 (Million Units)
Table 23.645 Prefilled Syringes Market for Other Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.646 Prefilled Syringes Market for Other Disorders: Share of Peptide, Conservative Scenario, 2020-2030 (USD Million)
Table 23.647 Prefilled Syringes Market for Other Disorders: Share of Peptide, Base Scenario, 2020-2030 (USD Million)
Table 23.648 Prefilled Syringes Market for Other Disorders: Share of Peptide, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.649 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (Million Units)
Table 23.650 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (Million Units)
Table 23.651 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.652 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Conservative Scenario, 2020-2030 (USD Million)
Table 23.653 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Base Scenario, 2020-2030 (USD Million)
Table 23.654 Prefilled Syringes Market for Other Disorders: Share of Small Molecules, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.655 Prefilled Syringes Market for Other Disorders: Share of North America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.656 Prefilled Syringes Market for Other Disorders: Share of North America, Base Scenario, 2020-2030 (Million Units)
Table 23.657 Prefilled Syringes Market for Other Disorders: Share of North America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.658 Prefilled Syringes Market for Other Disorders: Share of North America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.659 Prefilled Syringes Market for Other Disorders: Share of North America, Base Scenario, 2020-2030 (USD Million)
Table 23.660 Prefilled Syringes Market for Other Disorders: Share of North America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.661 Prefilled Syringes Market for Other Disorders: Share of Europe, Conservative Scenario, 2020-2030 (Million Units)
Table 23.662 Prefilled Syringes Market for Other Disorders: Share of Europe, Base Scenario, 2020-2030 (Million Units)
Table 23.663 Prefilled Syringes Market for Other Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.664 Prefilled Syringes Market for Other Disorders: Share of Europe, Conservative Scenario, 2020-2030 (USD Million)
Table 23.665 Prefilled Syringes Market for Other Disorders: Share of Europe, Base Scenario, 2020-2030 (USD Million)
Table 23.666 Prefilled Syringes Market for Other Disorders: Share of Europe, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.667 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (Million Units)
Table 23.668 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (Million Units)
Table 23.669 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.670 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Conservative Scenario, 2020-2030 (USD Million)
Table 23.671 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Base Scenario, 2020-2030 (USD Million)
Table 23.672 Prefilled Syringes Market for Other Disorders: Share of Asia Pacific, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.673 Prefilled Syringes Market for Other Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (Million Units)
Table 23.674 Prefilled Syringes Market for Other Disorders: Share of Latin America, Base Scenario, 2020-2030 (Million Units)
Table 23.675 Prefilled Syringes Market for Other Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.676 Prefilled Syringes Market for Other Disorders: Share of Latin America, Conservative Scenario, 2020-2030 (USD Million)
Table 23.677 Prefilled Syringes Market for Other Disorders: Share of Latin America, Base Scenario, 2020-2030 (USD Million)
Table 23.678 Prefilled Syringes Market for Other Disorders: Share of Latin America, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.679 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (Million Units)
Table 23.680 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (Million Units)
Table 23.681 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (Million Units)
Table 23.682 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Conservative Scenario, 2020-2030 (USD Million)
Table 23.683 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Base Scenario, 2020-2030 (USD Million)
Table 23.684 Prefilled Syringes Market for Other Disorders: Share of Middle East and Africa, Optimistic Scenario, 2020-2030 (USD Million)
Table 23.685 Sales of Leading Drugs Available in Prefilled Syringes, 2018 (USD Billion)
Table 23.686 FDA Approved Biologics, 2009-2019
Table 23.689 Aptar Group: Annual Revenues, 2013-H1 2019 (USD Billion)
Table 23.690 Datwyler Group: Annual Revenues, 2013-H1 2019 (CHF Million)
Table 23.691 Sumitomo Rubber Industries: Annual Revenues, 2013-H1 2019 (JPY Billion)
Table 23.692 Sumitomo Rubber Industries: Revenue Distribution by Business Segment, 2018
Table 23.693 Prefilled Syringe Fill / Finish Service Providers: Distribution by Year of Establishment
Table 23.694 Prefilled Syringes Fill / Finish Service Providers: Distribution by Scale of Operation

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 3D Medicines
  2. Abbott
  3. AbbVie
  4. Abivax
  5. Ablynx
  6. Acceleron Pharma
  7. Accord Healthcare
  8. Activa Brand Products
  9. Adamis Pharmaceuticals
  10. Adimmune
  11. Adocia
  12. Advance Pharma Lab
  13. Aerpio Therapeutics
  14. Affibody
  15. Agenus 
  16. Aguettant
  17. Aijex Pharma International
  18. Ajinomoto Bio-Pharma Services
  19. Akeso Biopharma
  20. AKRA DERMOJET
  21. Akums Drugs & Pharmaceuticals
  22. Al Biosciences
  23. Alder BioPharmaceuticals
  24. Alexion
  25. Alfa Corpuscles
  26. Alfasigma
  27. Alkermes
  28. Allergan
  29. Alnylam Pharmaceuticals
  30. Alphamab Jilin
  31. Altor BioScience
  32. Alvogen
  33. Alvotech
  34. Alzheimer's Association
  35. AMAG Pharmaceuticals 
  36. Amega Biotech
  37. Amgen
  38. AMRI
  39. AnaptysBio
  40. Andes Biotechnologies
  41. Antares Pharma
  42. Antev 
  43. Apellis Pharmaceuticals 
  44. APL (Apotek Produktion & Laboratorier)
  45. Apobiologix 
  46. Aptar Pharma
  47. Aquabiliti
  48. Araclon Biotech
  49. Archivel Farma
  50. Arecor
  51. Arrowhead Pharmaceuticals
  52. Arte 
  53. Asarina Pharma
  54. Ascendis Pharma
  55. ASIT biotech
  56. Assistance Publique Hôpitaux de Paris
  57. Astellas Pharma
  58. AstraZeneca
  59. AV7 
  60. Axon Neuroscience
  61. B. Braun Medical
  62. Bavarian Nordic
  63. Baxalta
  64. Baxter
  65. Bayer
  66. Becton Dickinson
  67. Bespak
  68. Beximco Pharma
  69. Biocad
  70. Biocon
  71. Biocorp
  72. Biogen
  73. BioGenCell
  74. Bioinova
  75. BioLineRx
  76. BioMarin Pharmaceutical
  77. BioMimetix
  78. BioPharma Solutions (a business unit of Baxter)
  79. BioValve Technologies
  80. BirgiMefar
  81. Boehringer Ingelheim
  82. Bone Therapeutics
  83. Boryung Pharmaceutical
  84. Boston Biomedical
  85. Boston Pharmaceuticals
  86. Bracco Diagnostics
  87. Braeburn Pharmaceuticals
  88. Bristol-Myers Squibb
  89. Brooklyn ImmunoTherapeutics
  90. Caladrius Biosciences
  91. Camurus
  92. CARBOGEN AMCIS
  93. Cardinal Health
  94. Catalent
  95. Catalyst Biosciences
  96. CeleCor Therapeutics
  97. Celgene
  98. Celldex Therapeutics
  99. Celltrion
  100. Cenexi
  101. Centrexion Therapeutics
  102. CinnaGen
  103. Ciron Drugs
  104. Civi Biopharma
  105. Coherus Biosciences
  106. Consort Medical
  107. Corden Pharma
  108. Corvidia Therapeutics
  109. Covidien
  110. Credence Medsystems
  111. CrossJect
  112. CSL Behring
  113. CSPC ZhongQi Pharmaceutical Technology
  114. CytoDyn
  115. Daewoong Pharmaceutical
  116. Daiichi Sankyo
  117. DALI Medical Devices
  118. Datwlyer
  119. Delpharm 
  120. DiaMedica Therapeutics
  121. Dicerna Pharmaceuticals
  122. Dr. Reddy's Laboratory
  123. Dynavax Technologies
  124. E3D
  125. Eisai
  126. Elcam Medical
  127. Eli Lilly
  128. Eloxx Pharmaceuticals
  129. Emcure Pharmaceuticals
  130. EMD Serono
  131. Emergent BioSolutions
  132. Enzon Pharma
  133. Ever Pharma
  134. Excelsior Medical
  135. Ferring Pharmaceuticals
  136. Follicum
  137. Foresee Pharmaceutical
  138. Fresenius Kabi
  139. Fujifilm Kyowa Kirin Biologics
  140. Future Injection Technologies
  141. Galapagos 
  142. GC Pharma
  143. GE Healthcare
  144. Genentech
  145. Generon (Shanghai) 
  146. Genexine
  147. Genocea Biosciences
  148. Genzyme
  149. GERCOR
  150. Gerresheimer
  151. Getz Pharma
  152. Gland Pharma
  153. GSK
  154. Guerbet
  155. HAL Allergy
  156. Hanmi Pharmaceutical
  157. Harbour BioMed
  158. Haselmeier
  159. Healthcare Pharmaceuticals
  160. Helixmith
  161. Hengrui Yuanzheng Bio-Technology
  162. Heron Therapeutics
  163. Hetero Drugs
  164. Hexal
  165. IDT Biologika
  166. Iltoo Pharma
  167. Il-Yang Pharmaceutical
  168. Immune Response BioPharma
  169. ImmunoVaccine
  170. Immunovant Sciences
  171. Immutep Australia
  172. Injecto
  173. Injex
  174. Inmune Bio
  175. Innovent Biologics
  176. Inovio Pharmaceuticals
  177. Intas Pharmaceuticals
  178. Intron Biotechnology
  179. Ionis Pharmaceuticals
  180. Ipsen
  181. ISU Abxis
  182. Italfarmaco
  183. Izana Bioscience
  184. J.O. Pharma
  185. Janssen
  186. Jiangsu Hansoh Pharmaceutical
  187. Jiangsu HengRui Medicine
  188. Jiangsu Hualan Pharmaceutical New Material
  189. Jiangsu T-Mab Biopharma
  190. Jiangxi Sanxin Medtec
  191. Jinan Youlyy Industrial
  192. Johnson & Johnson
  193. Kaleo Pharma
  194. Kang Stem Biotech
  195. Kemwell Biopharma
  196. KeyBioscience
  197. Kezar Life Sciences
  198. Kiniksa Pharmaceuticals
  199. Kyowa Hakko Kirin
  200. La Jolla Pharmaceutical
  201. Laboratorios SALVAT 
  202. LEO Pharma
  203. LG Chem
  204. LIB Therapeutics
  205. Lonstroff
  206. Lonza
  207. Lundbeck
  208. Luye Pharma
  209. M3 Biotechnology
  210. Mada Medical Products
  211. Mallinckrodt
  212. Medefil
  213. Medicago
  214. MedicalChain International
  215. Medigen Vaccine Biologics
  216. MedImmune
  217. MedPro Safety Products
  218. Medtronic
  219. MedxL
  220. Merck
  221. Merck Serono 
  222. Meridian
  223. Merit Medical
  224. Mika Medical
  225. Millendo Therapeutics 
  226. Millennium Pharmaceuticals
  227. Minervax
  228. miRagen Therapeutics
  229. Mithra Pharmaceuticals
  230. Mitsubishi Tanabe
  231. Modus Therapeutics
  232. Mologen
  233. Mylan
  234. Nektar Therapeutics
  235. Nemera
  236. NeoImmuneTech
  237. Neumedicines
  238. Neuraly
  239. NGM Biopharmaceuticals
  240. Ningbo Zhengli Pharmaceutical Packing
  241. NIPRO
  242. Nora Therapeutics
  243. Nordic Bioscience
  244. NovaDigm Therapeutics
  245. Novartis
  246. Novavax
  247. Novo Nordisk
  248. NPS Pharmaceuticals (a subsidiary of Shire)
  249. Nuance Designs
  250. Nurse Assist
  251. OBI Pharma
  252. OliPass 
  253. Olix Pharmaceuticals
  254. Ology Bioservices
  255. Omeros 
  256. Ompi
  257. Oncobiologics
  258. Oncolix 
  259. OncoPep
  260. OncoTherapy Science
  261. Oncovir
  262. OPKO Health
  263. Optimum Medical
  264. Orphan Disease Treatment Institute
  265. Osivax
  266. Otsuka Pharmaceutical
  267. Oval Medical Technologies
  268. Owen Mumford
  269. PA Consulting
  270. Palatin Technologies
  271. Patheon
  272. PCI Pharma Services
  273. PegBio
  274. PenJet
  275. Pfizer
  276. Pfizer CentreOne
  277. PharmaJet
  278. PhaseBio Pharmaceuticals
  279. PHC Injection Device Technologies
  280. Piramal Enterprises
  281. Pisa Farmaceutica
  282. Plas-Tech Engineering
  283. Pluristem Therapeutics
  284. Polaris Group
  285. PRA Health Sciences
  286. Primequal
  287. ProJect Pharmaceutics
  288. Promius Pharma
  289. Protagonist Therapeutics
  290. Proteo Biotech
  291. Qilu Pharmaceutical 
  292. Qu Biologics
  293. Quratis
  294. Ra Pharmaceuticals
  295. Rafa Laboratories
  296. Raumedic
  297. Regenera Pharma 
  298. Regeneron
  299. Reliance Life Sciences
  300. REMD Biotherapeutics
  301. Rentschler Biopharma
  302. Retractable Technologies
  303. Revolutions Medical
  304. RHEACELL
  305. Rhythm Pharmaceuticals
  306. Roche
  307. Roselabs biosciences
  308. Rovi Pharmaceutical
  309. R-Pharm
  310. Samsung Bioepis
  311. Samsung Biologics
  312. Sandoz
  313. Sanofi
  314. SCHERDEL Medtec
  315. Schering Medipharm
  316. Schott
  317. Schott-Kaisha
  318. Seqirus
  319. Serina Therapeutics
  320. Shandong Pharmaceutical Glass
  321. Shandong Weigao
  322. Shandong Zibo Minkang Pharmaceutical Packing
  323. Shanghai Biomabs Pharmaceutical
  324. Shenyang Sunshine Pharmaceutical
  325. Shin Yan Sheno Precision Industrial
  326. Shire
  327. SHL Group
  328. Siegfried Holding
  329. Sinocelltech
  330. SiO2 Medical Products
  331. Smiths Medical
  332. Swedish Orphan Biovitrum (SOBI)
  333. Spectrum Pharmaceuticals
  334. Splash Pharmaceuticals
  335. Square Pharmaceuticals
  336. SRI International
  337. Stealth BioTherapeutics
  338. Sun BioPharma
  339. Sun Pharma
  340. Suzuken
  341. SynDevRx
  342. Synermore Biologics 
  343. Taisei Kako
  344. Takeda
  345. Terumo Europe
  346. Teva Pharmaceutical
  347. The Medical House
  348. The Medicines Company
  349. The National Medical Products
  350. Themis Bioscience
  351. Therachon 
  352. TikoMed 
  353. Tip-Top
  354. Tolmar
  355. Transcoject
  356. Transgene
  357. Troikaa
  358. Turnstone Biologics
  359. Tyfill Pharmapack 
  360. UCB Biopharma
  361. Union Medico
  362. United Neuroscience
  363. US Medical Instruments
  364. Vaccibody
  365. Vaccitech 
  366. Valeant Pharmaceutical
  367. Valeritas
  368. Valneva
  369. Vaxine 
  370. Vetter Pharma
  371. Viela Bio
  372. ViiV Healthcare
  373. Vir Biotechnology
  374. Viriom
  375. Vitaeris
  376. VLP Therapeutics
  377. West Pharmaceutical
  378. Xbiotech
  379. XEME Biopharma
  380. YangZhong Wealth Metal
  381. YL Biologics 
  382. Ypsomed
  383. Zealand Pharma
  384. Zhejiang Huahai Pharmaceutical
  385. Zogenix
  386. ZymoGenetics

Segmentation

The financial opportunity within the prefilled syringes market has been analyzed across the following segments:

  • Target therapeutic area
    • Autoimmune disorders
    • Infectious diseases
    • Neurological disorders
    • Blood disorders
    • Oncological disorders
    • Psychiatric disorders
    • Respiratory disorders
    • Cardiovascular disorders
    • Metabolic disorders
    • Ophthalmic diseases
    • Orthopedic disorders
    • Others
  • Type of syringe
    • Specialty syringes
  • Type of syringe barrel material
    • Glass
    • Plastic
  • Number of barrel chambers
    • Single chamber
    • Dual chamber
  • Key geographical regions 
    • North America
    • Europe
    • Latin America
    • Asia Pacific
    • Middle East and Africa

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com